[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 618
1. Kawamori T, Kitamura T, Watanabe K, Uchiya N, Maruyama T, Narumiya S, Sugimura T, Wakabayashi K: Prostaglandin E receptor subtype EP(1) deficiency inhibits colon cancer development. Carcinogenesis; 2005 Feb;26(2):353-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At 6 weeks of age 33 homozygous EP(1)-deficient (EP(1)(-/-)) mice and 28 wild-type (EP(1)(+/+)) mice were given i.p.
  • At 56 weeks of age all animals were killed and intestinal tumors were examined.
  • [MeSH-minor] Adenocarcinoma / chemically induced. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenoma / chemically induced. Adenoma / metabolism. Adenoma / pathology. Animals. Mice. Mice, Knockout. Protein Kinase C / metabolism. Receptors, Prostaglandin E, EP1 Subtype

  • COS Scholar Universe. author profiles.
  • Guide to Pharmacology. gene/protein/disease-specific - EP1 receptor - data and references .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15564292.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ptger1 protein, mouse; 0 / Receptors, Prostaglandin E; 0 / Receptors, Prostaglandin E, EP1 Subtype; EC 2.7.1.- / protein kinase N; EC 2.7.11.13 / Protein Kinase C; MO0N1J0SEN / Azoxymethane
  •  go-up   go-down


2. Hirahashi M, Yao T, Matsumoto T, Nishiyama K, Oya M, Iida M, Tsuneyoshi M: Intramucosal gastric adenocarcinoma of poorly differentiated type in the young is characterized by Helicobacter pylori infection and antral lymphoid hyperplasia. Mod Pathol; 2007 Jan;20(1):29-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intramucosal gastric adenocarcinoma of poorly differentiated type in the young is characterized by Helicobacter pylori infection and antral lymphoid hyperplasia.
  • Twenty-three surgically resected specimens of young patients (under 30 years of age; young group) with intramucosal cancer of poorly differentiated type and 42 surgically resected specimens of elderly patients (more than 40 years of age; elderly group) with tumors of the identical depth and histological type were examined.
  • Within the background mucosa, antral chronic inflammatory infiltrates with lymphoid-follicle hyperplasia were more severe, and intestinal metaplasia was less frequent in the young group than in the elderly group.
  • Intramucosal gastric adenocarcinomas of poorly differentiated type in the young may be associated with H. pylori infection with antral chronic inflammation with lymphoid-follicle hyperplasia, regardless of the existence of intestinal metaplasia within the background gastric mucosa.
  • [MeSH-major] Adenocarcinoma / pathology. Gastric Mucosa / pathology. Helicobacter Infections / pathology. Helicobacter pylori / isolation & purification. Lymphoid Tissue / pathology. Pyloric Antrum / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17041565.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Hart WR: Borderline epithelial tumors of the ovary. Mod Pathol; 2005 Feb;18 Suppl 2:S33-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Typically, borderline tumors are noninvasive neoplasms that have nuclear abnormalities and mitotic activity intermediate between benign and malignant tumors of similar cell type.
  • The most common and best understood are serous borderline tumors and mucinous borderline tumors of intestinal type, which are the subject of this review.
  • The mucinous borderline tumors of intestinal type have a different set of considerations, including: their frequently heterogeneous composition with coexisting benign, borderline and malignant elements; the classification and significance of accompanying noninvasive carcinoma; the recognition of stromal invasion, including microinvasion and expansile invasion; and, the historically misunderstood relationship to pseudomyxoma peritonei.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15761465.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 93
  •  go-up   go-down


Advertisement
4. Vereczkey I, Tóth E, Orosz Z: [Diagnostic problems of ovarian mucinous borderline tumors]. Magy Onkol; 2009 Jun;53(2):127-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • About 15-20% of all ovarian epithelial neoplasms are of borderline type (or atypical proliferative or carcinoma of low malignant potential) and about 5-7% are mucinous type, which are the second most common type behind the serous borderline tumors.
  • To diagnose the intraepithelial carcinoma, to detect the microinvasion and the expansive invasion in a mucinous borderline tumor, to differentiate from the metastasis of colorectal tumors may be very problematic in the majority of the cases.
  • Eight out of 11 were intestinal type while three were cervical (mullerian) type.
  • In 5 cases our diagnosis was intraepithelial carcinoma and in 5 cases we found microinvasion.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Biomarkers, Tumor / analysis. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581178.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CDX2 protein, human; 0 / GPI-Linked Proteins; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7; 0 / Membrane Glycoproteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / mesothelin
  •  go-up   go-down


5. Tanaka S, Oka S, Kaneko I, Hirata M, Mouri R, Kanao H, Yoshida S, Chayama K: Endoscopic submucosal dissection for colorectal neoplasia: possibility of standardization. Gastrointest Endosc; 2007 Jul;66(1):100-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The rate of perforation was investigated with respect to the type of knife used for ESD and the period after the induction of ESD.
  • [MeSH-major] Adenocarcinoma / surgery. Colonoscopy / methods. Colorectal Neoplasms / surgery. Dissection / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Male. Middle Aged. Practice Guidelines as Topic. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17591481.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Tanaka K, Toyoda H, Inoue H, Hamada Y, Aoki M, Kosaka R, Takamura M, Imoto I: Depressed-type early duodenal carcinoma (carcinoma in situ) observed by enhanced magnification endoscopy. Endoscopy; 2007 Feb;39 Suppl 1:E125-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Depressed-type early duodenal carcinoma (carcinoma in situ) observed by enhanced magnification endoscopy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma in Situ / diagnosis. Duodenal Neoplasms / diagnosis. Duodenoscopy. Image Enhancement
  • [MeSH-minor] Aged. Biopsy. Coloring Agents. Female. Humans. Indigo Carmine. Intestinal Mucosa / pathology

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. INDIGO .
  • Hazardous Substances Data Bank. Indigotindisulfonate sodium .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17440853.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Coloring Agents; D3741U8K7L / Indigo Carmine
  •  go-up   go-down


7. Chebib I, Beck PL, Church NG, Medlicott SA: Gastric pouch adenocarcinoma and tubular adenoma of the pylorus: a field effect of dysplasia following bariatric surgery. Obes Surg; 2007 Jun;17(6):843-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric pouch adenocarcinoma and tubular adenoma of the pylorus: a field effect of dysplasia following bariatric surgery.
  • There are reports of gastric carcinoma following bariatric surgery, but it is unclear if these procedures predispose to malignancy.
  • Histology confirmed an intestinal type of gastric adenocarcinoma arising in a background of H. pylori-negative gastritis with atrophy, foveolar hyperplasia and intestinal metaplasia.
  • The pathogenesis of gastric pouch carcinoma is discussed.
  • [MeSH-major] Adenocarcinoma / etiology. Adenoma / etiology. Gastroplasty. Postoperative Complications. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Obes Surg. 2007 Jul;17(7):996
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Obes Surg. 1995 Nov;5(4):383-386 [10733831.001]
  • [Cites] Obes Surg. 2003 Oct;13(5):800-2 [14627482.001]
  • [Cites] BMJ. 1991 Jun 1;302(6788):1302-5 [2059685.001]
  • [Cites] Obes Surg. 2004 Apr;14(4):559-61 [15130239.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1132-6 [1891021.001]
  • [Cites] Mutat Res. 1987 Mar;177(1):35-43 [2881202.001]
  • [Cites] Cancer. 2001 May 1;91(9):1732-8 [11335898.001]
  • [Cites] Obes Surg. 2006 Dec;16(12):1656-61 [17217643.001]
  • [Cites] Cancer. 1989 Aug 1;64(3):698-703 [2743264.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):51-8 [9671066.001]
  • [Cites] World J Gastroenterol. 2001 Aug;7(4):563-5 [11819830.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1532-5 [8348487.001]
  • [Cites] Obes Surg. 1996 Feb;6(1):66-70 [10731254.001]
  • [Cites] Dig Dis. 1998 May-Jun;16(3):159-68 [9618135.001]
  • [Cites] Cancer. 1996 Dec 1;78(11):2288-99 [8940997.001]
  • [Cites] Obes Surg. 2002 Feb;12(1):118-20 [11868287.001]
  • [Cites] JSLS. 2004 Oct-Dec;8(4):372-5 [15554284.001]
  • [Cites] Int J Cancer. 1985 Feb 15;35(2):173-7 [3871738.001]
  • [Cites] J Natl Cancer Inst Monogr. 1992;(12):75-8 [1616814.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 Sep-Oct;1(6):455-61 [1302557.001]
  • [Cites] Ann Surg. 1989 Aug;210(2):159-64 [2757419.001]
  • [Cites] JAMA. 2003 Jul 2;290(1):66-72 [12837713.001]
  • [Cites] Obes Surg. 2002 Oct;12(5):693-4 [12448394.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2004 Dec;18(6):1117-23 [15561642.001]
  • (PMID = 17879590.001).
  • [ISSN] 0960-8923
  • [Journal-full-title] Obesity surgery
  • [ISO-abbreviation] Obes Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Gasparini G, Inelmen EM, Enzi G, Santoro C, Sergi G, Cardin F, Terranova O: Clinical and prognostic aspects of gastric carcinoma in the elderly. J Gastrointest Surg; 2006 Mar;10(3):395-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and prognostic aspects of gastric carcinoma in the elderly.
  • The aim of the present study was to analyze the influence of various factors on the prognosis for elderly patients with gastric carcinoma.
  • They all had a histologically confirmed diagnosis of gastric adenocarcinoma.
  • On univariate analysis, significant prognostic factors in the two age groups were gender, stage, histotype (Lauren's intestinal type), Charlson index, and type of surgery (curative resection, palliative resection, and no surgery).
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):515-9 [10947020.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 7;88(15):1031-8 [8683633.001]
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):520-5 [10947021.001]
  • [Cites] Tumori. 2002 Jan-Feb;88(1 Suppl 1):S51-2 [11989924.001]
  • [Cites] Aust N Z J Surg. 2000 Apr;70(4):254-7 [10779055.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1582-7 [9552069.001]
  • [Cites] Suppl Tumori. 2003 Sep-Oct;2(5):S31-4 [12914387.001]
  • [Cites] World J Surg. 2000 Apr;24(4):465-72 [10706921.001]
  • [Cites] Oncology (Williston Park). 2002 Feb;16(2):183-9; discussion 194-6, 199 [11866135.001]
  • [Cites] Suppl Tumori. 2003 Sep-Oct;2(5):S35-8 [12914388.001]
  • [Cites] World J Surg. 1984 Jun;8(3):315-20 [6464488.001]
  • [Cites] Age Ageing. 2003 Sep;32(5):484-6 [12957994.001]
  • [Cites] Eur J Surg Oncol. 2001 Aug;27(5):451-3 [11504514.001]
  • [Cites] J Am Geriatr Soc. 1997 Apr;45(4):482-8 [9100719.001]
  • [Cites] J Clin Gastroenterol. 2002 Jul;35(1):29-34 [12080223.001]
  • [Cites] Minerva Chir. 2004 Oct;59(5):479-87 [15494675.001]
  • [Cites] Gastric Cancer. 2004;7(3):154-9 [15449203.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 15;89(20):1489-97 [9337345.001]
  • [Cites] Am Surg. 1987 Mar;53(3):170-3 [3826909.001]
  • [Cites] Surg Oncol. 2004 Dec;13(4):235-8 [15615661.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2004;18 Suppl:73-81 [15588798.001]
  • (PMID = 16504885.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Collado B, Carmena MJ, Sánchez-Chapado M, Ruíz-Villaespesa A, Bajo AM, Fernández-Martínez AB, Varga JL, Schally AV, Prieto JC: Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog. Int J Oncol; 2005 Jun;26(6):1629-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog.
  • Vasoactive intestinal peptide (VIP) functions as a mitogenic agent in the human prostate gland acting by autocrine/paracrine mechanisms.
  • Here we extend knowledge on the VIP system (expression of VIP and VIP receptors, functionality of VIP receptors) at this level by analyzing the differences between human normal prostate and prostate carcinoma specimens.
  • RT-PCR showed the expression of mRNA for VIP in normal and malignant tissues, whereas VIP levels, as measured by enzyme immuno-analysis, were about two times higher in adenocarcinoma samples.
  • The results further explain the mechanisms of the autocrine/paracrine actions of VIP in human prostate and prostatic carcinoma through the observation of differences between healthy tissue and malignant transformation.
  • [MeSH-major] Growth Hormone-Releasing Hormone / analogs & derivatives. Growth Hormone-Releasing Hormone / pharmacology. Prostatic Neoplasms / chemistry. Receptors, Vasoactive Intestinal Peptide / analysis. Vasoactive Intestinal Peptide / analysis. Vasoactive Intestinal Peptide / antagonists & inhibitors
  • [MeSH-minor] Aged. Humans. Immunoenzyme Techniques. Male. Middle Aged. RNA, Messenger / analysis. Receptors, Cell Surface / analysis. Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide. Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I. Receptors, Vasoactive Intestinal Peptide, Type II. Receptors, Vasoactive Intestinal Polypeptide, Type I. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870879.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ADCYAP1R1 protein, human; 0 / JV 1-53; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide; 0 / Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; 0 / Receptors, Vasoactive Intestinal Peptide; 0 / Receptors, Vasoactive Intestinal Peptide, Type II; 0 / Receptors, Vasoactive Intestinal Polypeptide, Type I; 0 / VIPR1 protein, human; 0 / VIPR2 protein, human; 37221-79-7 / Vasoactive Intestinal Peptide; 9034-39-3 / Growth Hormone-Releasing Hormone
  •  go-up   go-down


10. Carter JT, Grenert JP, Rubenstein L, Stewart L, Way LW: Tumors of the ampulla of vater: histopathologic classification and predictors of survival. J Am Coll Surg; 2008 Aug;207(2):210-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We speculated that this might reflect the presence of two kinds of ampullary adenocarcinoma: pancreaticobiliary and intestinal.
  • Patients with pancreaticobiliary ampullary adenocarcinomas presented with jaundice more often than those with the intestinal kind (p = 0.01) and had worse survival.
  • CONCLUSIONS: In addition to other factors, tumor type (intestinal versus pancreaticobiliary) had a major effect on survival in patients with ampullary adenocarcinoma.
  • The current concept of ampullary adenocarcinoma as a unique entity, distinct from duodenal and pancreatic adenocarcinoma, might be wrong.
  • Intestinal ampullary adenocarcinomas behaved like their duodenal counterparts, but pancreaticobiliary ones were more aggressive and behaved like pancreatic adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656049.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Santini D, Angeletti S, Ruzzo A, Dicuonzo G, Galluzzo S, Vincenzi B, Calvieri A, Pizzagalli F, Graziano N, Ferraro E, Lorino G, Altomare A, Magnani M, Graziano F, Tonini G: Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin Exp Immunol; 2008 Dec;154(3):360-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes.
  • In the subgroup of patients with intestinal-type gastric cancer, a significant risk of gastric cancer was associated with TLR-4 Thr399Ile genotype (P = 0.006).
  • An increased risk for intestinal gastric cancer in carriers of the TLR4 Thr399Ile allele was observed.
  • [MeSH-major] Adenocarcinoma / genetics. Polymorphism, Genetic. Stomach Neoplasms / genetics. Toll-Like Receptor 4 / genetics

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2006 Jul 1;177(1):322-32 [16785528.001]
  • [Cites] Oncogene. 2008 Jan 7;27(2):244-52 [18176606.001]
  • [Cites] Nat Genet. 2000 Jun;25(2):187-91 [10835634.001]
  • [Cites] Biotechniques. 2001 Jul;31(1):22-4 [11464514.001]
  • [Cites] Genome Biol. 2002 Jul 29;3(8):REVIEWS3011 [12186654.001]
  • [Cites] Crit Care. 2003 Feb;7(1):23-38 [12617738.001]
  • [Cites] J Exp Med. 2003 Jun 16;197(12):1787-91 [12796470.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):32552-60 [12807870.001]
  • [Cites] Scand J Infect Dis. 2003;35(9):555-62 [14620134.001]
  • [Cites] Nagoya J Med Sci. 2003 Nov;66(3-4):103-17 [14727687.001]
  • [Cites] Clin Exp Immunol. 2004 Jun;136(3):521-6 [15147355.001]
  • [Cites] Nat Rev Immunol. 2004 Jul;4(7):499-511 [15229469.001]
  • [Cites] Nat Immunol. 2004 Oct;5(10):975-9 [15454920.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 6;97(7):525-32 [15812078.001]
  • [Cites] Cytokine. 2005 Jun 7;30(5):264-8 [15927851.001]
  • [Cites] Nat Rev Immunol. 2005 Jun;5(6):446-58 [15928677.001]
  • [Cites] Nat Rev Immunol. 2006 Jan;6(1):9-20 [16493424.001]
  • [Cites] Inflamm Bowel Dis. 2006 Jul;12(7):641-50 [16804402.001]
  • [Cites] Dig Dis Sci. 2007 Jan;52(1):254-61 [17171451.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):352-5 [17301271.001]
  • [Cites] J Commun Dis. 2006 Mar;38(3):230-45 [17373355.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2007;21(2):281-97 [17382277.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):905-12 [17324405.001]
  • [Cites] Trends Pharmacol Sci. 2007 Apr;28(4):162-5 [17331592.001]
  • [Cites] BMC Cancer. 2007;7:70 [17462092.001]
  • [Cites] Hum Immunol. 2007 Nov;68(11):901-7 [18082569.001]
  • [Cites] Nature. 2000 Mar 23;404(6776):398-402 [10746728.001]
  • (PMID = 18826495.001).
  • [ISSN] 1365-2249
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / TLR4 protein, human; 0 / Toll-Like Receptor 4
  • [Other-IDs] NLM/ PMC2633233
  •  go-up   go-down


12. Monte MJ, Ballestero MR, Briz O, Perez MJ, Marin JJ: Proapoptotic effect on normal and tumor intestinal cells of cytostatic drugs with enterohepatic organotropism. J Pharmacol Exp Ther; 2005 Oct;315(1):24-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proapoptotic effect on normal and tumor intestinal cells of cytostatic drugs with enterohepatic organotropism.
  • The proapoptotic effect of cisplatin bile acid derivatives Bamet-R2 [cis-diamminechloro-cholylglycinate-platinum(II)] and Bamet-UD2 [cis-diammine-bisursodeoxycholate-platinum(II)], developed to treat liver and intestinal tumors, was investigated in vitro using human enterohepatic cells HepG2 (hepatoblastoma), LS 174T (colon adenocarcinoma), and its cisplatin-resistant subline LS 174T/R.
  • Uptake by wild-type tumor cells was higher for Bamets than for cisplatin.
  • These results indicate that Bamet-UD2 overcomes the resistance to cisplatin when this is due in part to enhanced ability of intestinal tumors to reduce intracellular cisplatin contents.
  • Moreover, its strong proapoptotic versus its weak pronecrotic effect together with its mild effect on normal tissues, including intestinal mucosa, may account for the high antitumor activity of Bamet-UD2 together with its very low toxicity.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Intestinal Neoplasms / drug therapy. Intestine, Small / drug effects. Organoplatinum Compounds / pharmacology. Ursodeoxycholic Acid / analogs & derivatives

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15985617.001).
  • [ISSN] 0022-3565
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bamet-UD2; 0 / DNA Adducts; 0 / Organoplatinum Compounds; 0 / diamminebis(ursodeoxycholate(O,O'))platinum(II); 724L30Y2QR / Ursodeoxycholic Acid
  •  go-up   go-down


13. Oh SY, Kwon HC, Kim SH, Jang JS, Kim MC, Kim KH, Han JY, Kim CO, Kim SJ, Jeong JS, Kim HJ: Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer. BMC Cancer; 2008;8:123
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • VEGF overexpression was more frequently observed in the old age group (> or = 60 years old) and the intestinal type (P = 0.013, P = 0.014, respectively).
  • [MeSH-major] Adenocarcinoma / blood. Hypoxia-Inducible Factor 1, alpha Subunit / biosynthesis. Stomach Neoplasms / blood. Tumor Suppressor Protein p53 / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis. Vascular Endothelial Growth Factor A / blood

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jun;62(3):179-213 [17324579.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1207-25 [11181687.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2911-6 [11306467.001]
  • [Cites] Mol Cell Biol. 2001 May;21(10):3436-44 [11313469.001]
  • [Cites] Cancer Metastasis Rev. 2007 Jun;26(2):281-90 [17603752.001]
  • [Cites] Nature. 1996 Jan 4;379(6560):88-91 [8538748.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):858-63 [8608475.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1661-8 [11410504.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5215-22 [11431362.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jul 1;128(1):31-4 [11454426.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6548-54 [11522653.001]
  • [Cites] Cancer Lett. 2002 Feb 25;176(2):215-23 [11804750.001]
  • [Cites] Ann Surg. 2002 Jul;236(1):37-42 [12131083.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(2):184-91 [12509950.001]
  • [Cites] Cancer Lett. 2003 Mar 31;192(2):215-25 [12668286.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):176-81 [12673675.001]
  • [Cites] Cancer Sci. 2003 Aug;94(8):735-40 [12901801.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):206-15 [14710231.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4109-17 [15217947.001]
  • [Cites] Eur Urol. 2004 Aug;46(2):200-8 [15245814.001]
  • [Cites] Mol Cell Biol. 1994 Sep;14(9):6264-77 [8065358.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):826-32 [9053510.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2067-72 [9179052.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8104-9 [9223322.001]
  • [Cites] Eur Surg Res. 1998;30(2):130-7 [9565747.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5678-80 [9865721.001]
  • [Cites] Histol Histopathol. 1999 Jan;14(1):279-84 [9987672.001]
  • [Cites] J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S407-9 [15838334.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):309-14 [11181778.001]
  • (PMID = 18452596.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Tumor Suppressor Protein p53; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2397429
  •  go-up   go-down


14. Murphy G, Pfeiffer R, Camargo MC, Rabkin CS: Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology; 2009 Sep;137(3):824-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Over 90% of lymphoepithelioma-like carcinomas were EBV positive, but only 15 studies reported any cases of this type; prevalence did not significantly differ between the more common diffuse (9.5%) [corrected] and intestinal (7.6%) [corrected] histologies.
  • [MeSH-minor] Adenocarcinoma / virology. Carcinoma / virology. Cardia / virology. Epstein-Barr Virus Infections / complications. Female. Gastric Stump. Humans. Male. Pyloric Antrum / virology. Sex Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Clin Cancer Res. 2005 Sep;24(3):379-85 [16270524.001]
  • [Cites] World J Gastroenterol. 2005 Oct 21;11(39):6096-103 [16273633.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Dec;24(4):547-53 [16471317.001]
  • [Cites] World J Gastroenterol. 2006 Mar 28;12(12):1842-8 [16609989.001]
  • [Cites] J Med Microbiol. 2006 Jul;55(Pt 7):905-11 [16772418.001]
  • [Cites] Int J Epidemiol. 2006 Oct;35(5):1270-1 [16980313.001]
  • [Cites] Am J Epidemiol. 2007 Jun 15;165(12):1424-33 [17420181.001]
  • [Cites] Nature. 2000 Mar 23;404(6776):398-402 [10746728.001]
  • [Cites] Gastroenterology. 2000 Jun;118(6):1031-8 [10833477.001]
  • [Cites] Pathol Int. 2000 Jun;50(6):486-92 [10886725.001]
  • [Cites] Am J Clin Pathol. 2000 Sep;114(3):354-63 [10989635.001]
  • [Cites] Mol Pathol. 2000 Oct;53(5):255-61 [11091849.001]
  • [Cites] Eur J Cancer Prev. 2001 Feb;10(1):69-75 [11263593.001]
  • [Cites] Jpn J Cancer Res. 2001 Sep;92(9):911-7 [11572757.001]
  • [Cites] Int J Cancer. 2001 Nov15;94(4):527-30 [11745439.001]
  • [Cites] Br J Cancer. 2002 Mar 4;86(5):702-4 [11875729.001]
  • [Cites] Scand J Gastroenterol. 2002 Jul;37(7):825-9 [12190097.001]
  • [Cites] J Clin Pathol. 2002 Sep;55(9):669-75 [12194996.001]
  • [Cites] J Med Virol. 2002 Nov;68(3):384-9 [12226826.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2008-9 [12242430.001]
  • [Cites] Gastric Cancer. 2002;5(4):213-9 [12491079.001]
  • [Cites] J Pathol. 2003 Feb;199(2):140-5 [12533825.001]
  • [Cites] J Pathol. 2003 Apr;199(4):447-52 [12635135.001]
  • [Cites] Arch Pathol Lab Med. 2003 Apr;127(4):478-80 [12683879.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):641-51 [12861059.001]
  • [Cites] Gastric Cancer. 2003;6(3):173-8 [14520531.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):664-70 [14966089.001]
  • [Cites] J Infect Dis. 2004 Jun 15;189(12):2271-81 [15181575.001]
  • [Cites] Oncol Rep. 2004 Nov;12(5):1093-8 [15492798.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] IARC Sci Publ. 1978;(20):167-89 [215514.001]
  • [Cites] Arch Surg. 1982 Mar;117(3):294-7 [7065870.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] Mod Pathol. 1990 May;3(3):377-80 [2163534.001]
  • [Cites] Am J Pathol. 1992 Apr;140(4):769-74 [1314023.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5455-9 [8390666.001]
  • [Cites] Am J Pathol. 1993 Nov;143(5):1250-4 [8238241.001]
  • [Cites] Lab Invest. 1994 Jul;71(1):73-81 [8041121.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9131-5 [8090780.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1158-63 [7943537.001]
  • [Cites] J Clin Pathol. 1994 Aug;47(8):695-8 [7962618.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):549-60 [7845680.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):952-9 [8622698.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):174-81 [8607441.001]
  • [Cites] Histopathology. 1996 Feb;28(2):121-7 [8834519.001]
  • [Cites] Int J Cancer. 1997 Feb 7;70(4):375-82 [9033642.001]
  • [Cites] Jpn J Cancer Res. 1997 Mar;88(3):262-6 [9140110.001]
  • [Cites] Pathol Int. 1997 Jun;47(6):360-7 [9211523.001]
  • [Cites] BMJ. 1998 May 16;316(7143):1507-10 [9582144.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:47-373 [9612712.001]
  • [Cites] Oral Oncol. 1998 Jan;34(1):15-23 [9659515.001]
  • [Cites] Pathol Res Pract. 1998;194(10):705-11 [9820867.001]
  • [Cites] J Clin Pathol. 1998 Sep;51(9):662-6 [9930069.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1582-6 [10364028.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):1214-9 [10370694.001]
  • [Cites] J Clin Gastroenterol. 1999 Jul;29(1):39-43 [10405229.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15730-5 [15498875.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Gut. 2007 Jul;56(7):918-25 [17317788.001]
  • [Cites] Gut. 2007 Dec;56(12):1671-7 [17627962.001]
  • [Cites] World J Gastroenterol. 2008 Feb 14;14(6):884-91 [18240345.001]
  • [Cites] Cancer Sci. 2008 Feb;99(2):195-201 [18271915.001]
  • [Cites] Aging Clin Exp Res. 2008 Apr;20(2):91-102 [18431075.001]
  • [Cites] Hepatogastroenterology. 2008 Jan-Feb;55(81):41-5 [18507075.001]
  • [Cites] Scand J Gastroenterol. 2008;43(6):669-74 [18569983.001]
  • [Cites] World J Gastroenterol. 2008 Jul 21;14(27):4347-51 [18666324.001]
  • [Cites] Int J Epidemiol. 2008 Oct;37(5):1158-60 [18832388.001]
  • [Cites] Gut. 2009 Jan;58(1):16-23 [18838486.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Gastroenterol. 2005 Jun;40(6):570-7 [16007390.001]
  • [ErratumIn] Gastroenterology. 2011 Mar;140(3):1109
  • (PMID = 19445939.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS424076; NLM/ PMC3513767
  •  go-up   go-down


15. Cho YE, Kim JY, Kim YW, Park JH, Lee S: Expression and prognostic significance of human growth and transformation-dependent protein in gastric carcinoma and gastric adenoma. Hum Pathol; 2009 Jul;40(7):975-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic significance of human growth and transformation-dependent protein in gastric carcinoma and gastric adenoma.
  • We investigated the expression profile of human growth and transformation-dependent protein using immunohistochemistry in gastric tissues including cancer (n = 138), adenoma (n = 37), intestinal metaplasia (n = 20), and normal gastric epithelium (n = 20), then correlated human growth and transformation-dependent protein expression in tumors with clinicopathologic features.
  • Human growth and transformation-dependent protein showed strong staining in the cytoplasm of intestinal-type adenocarcinoma and gastric adenoma, whereas normal gastric antral mucosa showed no staining.
  • These findings suggest that human growth and transformation-dependent protein expression is a common occurrence during the progression from a normal gastric mucosa to an intestinal-type carcinoma and may be associated with tumor cell proliferation activity.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Membrane Proteins / biosynthesis. Mitochondrial Proteins / biosynthesis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Intestinal Mucosa / metabolism. Kaplan-Meier Estimate. Ki-67 Antigen / biosynthesis. Male. Metaplasia / metabolism. Metaplasia / pathology. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269009.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FAM162A protein, human; 0 / Ki-67 Antigen; 0 / Membrane Proteins; 0 / Mitochondrial Proteins
  •  go-up   go-down


16. Maezato K, Nishimaki T, Oshiro M, Yamashiro T, Sasaki H, Sashida Y: Signet-ring cell carcinoma of the esophagus associated with Barrett's epithelium: report of a case. Surg Today; 2007;37(12):1096-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet-ring cell carcinoma of the esophagus associated with Barrett's epithelium: report of a case.
  • We herein report a case of infiltrative esophageal signet-ring cell carcinoma resembling gastric signet-ring cell carcinoma.
  • Grossly, the tumor was a diffusely infiltrative carcinoma involving the lower esophagus measuring 11 cm in diameter.
  • Histologically, the tumor was signet-ring cell carcinoma covered with normal squamous epithelium.
  • However, the most superficial part of the tumor center contained a region of Barrett's mucosa with incomplete-type intestinal metaplasia and a well-differentiated adenocarcinoma component with goblet cells.
  • The expression of cytokeratins 7 and 20 also indicated that both the Barrett's mucosa and the signet-ring cell carcinoma had an esophageal origin.
  • Esophageal signet-ring cell carcinoma with diffuse infiltrative growth is quite rare, and may need a special treatment strategy because of its highly aggressive behavior and poor treatment outcome.
  • [MeSH-major] Barrett Esophagus / complications. Carcinoma, Signet Ring Cell / pathology. Esophageal Neoplasms / pathology


17. Tatsuta M, Iishi H, Baba M, Uedo N, Ishihara R, Higashino K, Mukai M, Ishiguro S: Induction by lysophosphatidic acid of peritoneal and pleural metastases of intestinal cancers induced by azoxymethane in Wistar rats. Cancer Lett; 2005 Mar 10;219(2):137-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction by lysophosphatidic acid of peritoneal and pleural metastases of intestinal cancers induced by azoxymethane in Wistar rats.
  • The effects of 1-oleoyl lysophosphatidic acid on the induction of metastasis from intestinal adenocarcinomas induced in rats by azoxymethane and on RhoA activity in the tumors were investigated in male Wistar rats.
  • Although lysophosphatidic acid at both dosages had little or no effect on the location, histologic type, depth of involvement or infiltrating growth patterns of the tumors, its administration at both dosages significantly increased the incidence of vessel invasion of adenocarcinomas.
  • Our findings indicate that lysophosphatidic acid significantly increased the incidence of peritoneal and/or pleural metastases from intestinal adenocarcinomas induced in rats by azoxymethane through RhoA activation.
  • [MeSH-major] Adenocarcinoma / secondary. Intestinal Neoplasms / chemically induced. Lysophospholipids / pharmacology. Peritoneal Neoplasms / secondary. Pleural Neoplasms / secondary. rhoA GTP-Binding Protein / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15723712.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Lysophospholipids; 0 / Proliferating Cell Nuclear Antigen; 22002-87-5 / lysophosphatidic acid; EC 3.6.5.2 / rhoA GTP-Binding Protein; MO0N1J0SEN / Azoxymethane
  •  go-up   go-down


18. Perez-Ordoñez B: Hamartomas, papillomas and adenocarcinomas of the sinonasal tract and nasopharynx. J Clin Pathol; 2009 Dec;62(12):1085-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lesions of the sinonasal tract are uncommon, with most of the specimens seen by surgical pathologists consisting primarily of fragments of inflamed sinonasal mucosa or inflammatory polyps from patients with chronic rhinosinusitis, and the occasional squamous cell carcinoma.
  • The aim of this review is to present the pathological features of a group of infrequent epithelial surface and glandular lesions of the sinonasal tract which includes respiratory epithelial adenomatoid hamartoma, glandular (seromucinous) hamartoma, exophytic papilloma, inverted papilloma, cylindrical cell (oncocytic) papilloma, low-grade sinonasal adenocarcinoma and intestinal-type sinonasal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Hamartoma / pathology. Nasopharyngeal Neoplasms / pathology. Papilloma / pathology. Paranasal Sinus Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19946095.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 88
  •  go-up   go-down


19. Souza RF, Krishnan K, Spechler SJ: Acid, bile, and CDX: the ABCs of making Barrett's metaplasia. Am J Physiol Gastrointest Liver Physiol; 2008 Aug;295(2):G211-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Barrett's esophagus, a squamous-to-columnar cell metaplasia that develops as a result of chronic gastroesophageal reflux disease (GERD), is a risk factor for esophageal adenocarcinoma.
  • When mice are genetically engineered so that their gastric cells express Cdx, the stomach develops a metaplastic, intestinal-type epithelium similar to that of Barrett's esophagus.
  • Exposure to acid and bile has been shown to activate the Cdx promoter in certain esophageal cell lines, and Cdx expression has been found in inflamed esophageal squamous epithelium and in the specialized intestinal metaplasia of Barrett's esophagus.
  • Barrett's metaplasia must be sustained by stem cells, which might be identified by putative, intestinal stem cell markers like leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and doublecortin and CaM kinase-like-1 (DCAMKL-1).

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18556417.001).
  • [ISSN] 0193-1857
  • [Journal-full-title] American journal of physiology. Gastrointestinal and liver physiology
  • [ISO-abbreviation] Am. J. Physiol. Gastrointest. Liver Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX1 protein, human; 0 / CDX2 protein, human; 0 / Cdx2 protein, mouse; 0 / Homeodomain Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / LGR5 protein, human; 0 / Receptors, G-Protein-Coupled; 0 / Transcription Factors; EC 2.7.1.11 / DCLK1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Number-of-references] 78
  •  go-up   go-down


20. Vang R, Gown AM, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, Ronnett BM: Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol; 2006 Sep;30(9):1130-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report analysis of both coordinate expression profiles and staining distribution in 179 rigorously classified mucinous tumors in the ovary, including 53 primary tumors [35 atypical proliferative (borderline) mucinous tumors of gastrointestinal type and 18 invasive mucinous carcinomas] and 126 secondary tumors [28 colorectal adenocarcinomas, 54 appendiceal tumors (23 adenocarcinomas, 31 low-grade adenomatous mucinous tumors associated with pseudomyxoma peritonei), 14 pancreatic adenocarcinomas, 8 endocervical adenocarcinomas, 5 gastric adenocarcinomas, 4 gallbladder/biliary tract adenocarcinomas, and 13 adenocarcinomas of unknown primary sites).
  • A CK7+/CK20+ immunoprofile was the most common profile in primary ovarian tumors (74%), upper gastrointestinal tract tumors (78%), and endocervical tumors (88%) but was occasionally observed in lower intestinal tract tumors (colorectal: 11%; appendiceal: 13% of low-grade tumors, 35% of carcinomas).
  • A CK7-/CK20+ immunoprofile was the most common profile in lower intestinal tract tumors (79%) and was uncommon in upper gastrointestinal tract tumors (9%), rarely seen in primary ovarian tumors (4%), and not seen in endocervical tumors.
  • A CK7+/CK20- profile was observed in some primary ovarian (23%), upper gastrointestinal tract (13%), and endocervical tumors (13%) but not in lower intestinal tract tumors.
  • For CK20+ tumors, staining distribution was variable but often focal in primary ovarian tumors and nonlower intestinal tract tumors, whereas the pattern was almost always diffuse in lower intestinal tract tumors.
  • Immunohistochemical staining distribution can supplement CK7/CK20 coordinate expression profiles to distinguish subsets of primary ovarian and metastatic lower intestinal tract mucinous tumors having overlapping immunoprofiles but neither coordinate expression profiles nor staining distribution distinguishes primary ovarian tumors from the nonlower intestinal tract metastases.
  • [MeSH-major] Adenocarcinoma, Mucinous / chemistry. Keratins / analysis. Ovarian Neoplasms / chemistry
  • [MeSH-minor] Adenocarcinoma / chemistry. Coloring Agents. Female. Gastrointestinal Neoplasms / chemistry. Humans. Immunohistochemistry. Keratin-20. Keratin-7. Pseudomyxoma Peritonei / complications. Uterine Cervical Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16931958.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


21. Mackie S, Malik T, Khalil H: Endoscopic resection and topical 5-Fluorouracil as an alternative treatment to craniofacial resection for the management of primary intestinal-type sinonasal adenocarcinoma. Minim Invasive Surg; 2010;2010:750253
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic resection and topical 5-Fluorouracil as an alternative treatment to craniofacial resection for the management of primary intestinal-type sinonasal adenocarcinoma.
  • Introduction. Intestinal-type adenocarcinoma of the sinonasal tract is very rare and is responsible for less than 4% of tumours of the sinuses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22091355.001).
  • [ISSN] 2090-1453
  • [Journal-full-title] Minimally invasive surgery
  • [ISO-abbreviation] Minim Invasive Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3195981
  •  go-up   go-down


22. Colleypriest BJ, Palmer RM, Ward SG, Tosh D: Cdx genes, inflammation and the pathogenesis of Barrett's metaplasia. Trends Mol Med; 2009 Jul;15(7):313-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metaplasia is the conversion of one cell or tissue type to another and can predispose patients to neoplasia.
  • Perhaps one of the best-known examples of metaplasia is Barrett's metaplasia (BM), a pathological condition in which the distal oesophageal epithelium switches from stratified squamous to intestinal-type columnar epithelium.
  • BM predisposes to oesophageal adenocarcinoma and is the consequence of long-term acid bile reflux.
  • The incidence of BM and oesophageal adenocarcinoma has risen dramatically in recent years.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19564133.001).
  • [ISSN] 1471-499X
  • [Journal-full-title] Trends in molecular medicine
  • [ISO-abbreviation] Trends Mol Med
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300415; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDX1 protein, human; 0 / CDX2 Transcription Factor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  • [Number-of-references] 101
  •  go-up   go-down


23. El Ayoubi A, Poizat F, Garrel R, Costes V, Guerrier B, Essakalli L, Kzadri M, Crampette L: [Sinonasal adenocarcinomas reviewed. Prognostic value of WHO 2005 histological classification]. Ann Otolaryngol Chir Cervicofac; 2009 Sep;126(4):175-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The WHO 2005 histological classification separates sinonasal adenocarcinoma (ADC) into three classes: intestinal-type adenocarcinoma (ITAC), low-grade sinonasal ADC and high-grade sinonasal ADC.
  • Twelve patients were reclassified into the adenoid cystic carcinoma category and excluded from the study.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Ethmoid Sinus. Nose Neoplasms / classification. Nose Neoplasms / pathology. Paranasal Sinus Neoplasms / classification. Paranasal Sinus Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19591973.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7; 0 / Microfilament Proteins; 0 / Trans-Activators; 0 / villin; 156560-97-3 / Cdx-2-3 protein; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


24. Zhang J, Parwani AV, Ali SZ: Hepatocyte paraffin 1 immunoexpression in esophageal brush samples. Cancer; 2005 Oct 25;105(5):304-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intestinal metaplasia (IM) is often a component of Barrett esophagus (BE) and is characterized by a distinctive type of epithelium.
  • Because IM has the potential to progress to dysplasia or adenocarcinoma, an accurate identification of its presence is important clinically.
  • RESULTS: Among the samples of BE with IM, 9 of 11 samples (82%) were immunoreactive for Heppar-1, compared with 0 of 11 specimens of BE with only cardiac-type metaplasia.
  • [MeSH-minor] Adenocarcinoma / etiology. Aged. Aged, 80 and over. Antibodies, Monoclonal. Antibodies, Monoclonal, Humanized. Biomarkers / analysis. Cytological Techniques. Esophageal Neoplasms / etiology. Hepatocytes / metabolism. Humans. Immunoassay. Metaplasia. Middle Aged. Retrospective Studies. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer. 2006 Feb 25;108(1):73-4; author reply 74-5 [16104041.001]
  • (PMID = 15918175.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens; 0 / Biomarkers; 0 / veltuzumab
  •  go-up   go-down


25. Tajima Y, Yamazaki K, Makino R, Nishino N, Masuda Y, Aoki S, Kato M, Morohara K, Kusano M: Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach. Br J Cancer; 2007 Feb 26;96(4):631-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach.
  • Adenocarcinoma of the gastric cardia (C-Ca) is possibly a specific subtype of gastric carcinoma.
  • The purpose of this study was to clarify the differences in the clinicopathological characteristics between C-Ca and adenocarcinoma of the distal stomach (D-Ca), and also the differences in the expressions of gastric and intestinal phenotypic markers and genetic alterations between the two.
  • C-Ca was associated with a significantly higher incidence of differentiated-type tumours and lymphatic vessel invasion (LVI) as compared with D-Ca (72.2 vs 48.2%, P=0.0006 and 72.2 vs 55.3%, P=0.0232, respectively).
  • The incidence of undifferentiated-type tumours was significantly higher in cases with advanced-stage C-Ca than in those with early-stage C-Ca (5 vs 36.5%, P=0.0076).
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Biomarkers, Tumor / genetics. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic / genetics. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1994 Jun;129(6):609-14 [8204035.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):723-34 [7657100.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):999-1001 [7657131.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2015-21 [9164213.001]
  • [Cites] Int J Cancer. 1998 Mar 2;75(5):767-73 [9495247.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):28-32 [9988228.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1003-7 [10070955.001]
  • [Cites] Pathol Int. 1999 Jan;49(1):55-61 [10227725.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):874-9 [15681533.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Jun;132(6):363-75 [16447040.001]
  • [Cites] World J Gastroenterol. 2006 Jun 28;12(24):3803-9 [16804962.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 18;98(20):1445-52 [17047193.001]
  • [Cites] Mutat Res. 2000 Jul 20;452(1):83-90 [10894894.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1055-9 [11048797.001]
  • [Cites] Oncology. 2001;61(1):1-9 [11474241.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Sep;32(1):50-8 [11477661.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):592-8 [11522743.001]
  • [Cites] Oncology. 2001;61(3):212-20 [11574777.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2228-33 [11596042.001]
  • [Cites] Int J Cancer. 2002 Feb 10;97(5):562-6 [11807778.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):336-43 [11992401.001]
  • [Cites] Histopathology. 2002 Jul;41(1):56-64 [12121238.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):611-8 [12163385.001]
  • [Cites] Gastric Cancer. 2004;7(1):46-53 [15052440.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3082-90 [15131047.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1342-8 [15354218.001]
  • [Cites] Gan. 1968 Jun;59(3):251-8 [5726267.001]
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Gastroenterology. 1984 Mar;86(3):461-7 [6693012.001]
  • [Cites] Clin Exp Immunol. 1984 Feb;55(2):319-32 [6365376.001]
  • [Cites] J Clin Pathol. 1985 Sep;38(9):1002-6 [2931454.001]
  • [Cites] Hum Pathol. 1986 May;17(5):482-7 [3699811.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1094-8 [3607726.001]
  • [Cites] Int J Cancer. 1988 Feb 15;41(2):184-97 [3338870.001]
  • [Cites] Hum Pathol. 1988 Aug;19(8):942-8 [3402983.001]
  • [Cites] Acta Pathol Jpn. 1990 Jul;40(7):494-504 [2220396.001]
  • [Cites] CA Cancer J Clin. 1991 Jan-Feb;41(1):19-36 [1984806.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Hum Pathol. 1991 Nov;22(11):1158-61 [1743701.001]
  • [Cites] Int J Cancer. 1992 Jan 21;50(2):202-7 [1730514.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1088-93 [1739905.001]
  • [Cites] J Am Coll Surg. 1995 May;180(5):577-82 [7749534.001]
  • (PMID = 17262083.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2360051
  •  go-up   go-down


26. Xiao L, Wang YC, Li WS, Du Y: The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray. J Exp Clin Cancer Res; 2009;28:152
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These three markers were preferably expressed in the older patients with gastric cancer and intestinal-type carcinoma (p < 0.05).
  • Univariate analysis indicated that expression of mTOR and nuclear p-P70S6K was closely linked to favorable prognosis of the carcinoma patients (p < 0.05).

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5239-47 [9823338.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3581-7 [10446965.001]
  • [Cites] J Biol Chem. 2006 Mar 17;281(11):7357-63 [16407298.001]
  • [Cites] Endocrinology. 2006 May;147(5):2557-66 [16469801.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):81-9 [17200342.001]
  • [Cites] J Clin Pathol. 2007 Mar;60(3):273-7 [16714395.001]
  • [Cites] Cancer Lett. 2007 Jun 18;251(1):105-13 [17175097.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):9-22 [17613433.001]
  • [Cites] Cancer Lett. 2007 Aug 18;253(2):236-48 [17360108.001]
  • [Cites] Br J Cancer. 2007 Jul 16;97(2):218-22 [17622239.001]
  • [Cites] Trends Mol Med. 2007 Oct;13(10):433-42 [17905659.001]
  • [Cites] Clin Adv Hematol Oncol. 2007 Oct;5(10):772-4 [17998894.001]
  • [Cites] Mol Carcinog. 2008 Jun;47(6):446-57 [18058806.001]
  • [Cites] Breast Cancer Res Treat. 2008 Aug;110(3):477-83 [17805960.001]
  • [Cites] Virchows Arch. 2008 May;452(5):525-34 [18266006.001]
  • [Cites] Br J Cancer. 2009 Mar 10;100(5):782-8 [19223902.001]
  • [Cites] Med Oncol. 2010 Jun;27(2):255-61 [19301157.001]
  • [Cites] Oncogene. 2002 Jun 6;21(25):4032-41 [12037685.001]
  • [Cites] J Biol Chem. 2002 Aug 30;277(35):31423-9 [12087098.001]
  • [Cites] Arch Pharm Res. 2002 Oct;25(5):685-90 [12433206.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1543-50 [15083183.001]
  • [Cites] Exp Cell Res. 2004 Jun 10;296(2):183-95 [15149849.001]
  • (PMID = 20003385.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa
  • [Other-IDs] NLM/ PMC2797794
  •  go-up   go-down


27. Feagins LA, Souza RF: Molecular targets for treatment of Barrett's esophagus. Dis Esophagus; 2005;18(2):75-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The major risk factors for esophageal adenocarcinoma are gastroesophageal reflux disease (GERD) and its sequela, Barrett's esophagus.
  • In a minority of patients however, ongoing GERD leads to replacement of esophageal squamous mucosa with metaplastic, intestinal-type Barrett's mucosa.
  • In the setting of continued peptic injury, Barrett's mucosa can give rise to esophageal adenocarcinoma.
  • Despite the widespread use of potent acid suppressive therapies for patients with GERD, the incidence of esophageal adenocarcinoma, among white men in the USA, the UK and Europe has continued to rise.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16053481.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / 5T32DK-07745; United States / NIDDK NIH HHS / DK / DK63621
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Growth Inhibitors
  • [Number-of-references] 111
  •  go-up   go-down


28. Moss SF, Lee JW, Sabo E, Rubin AK, Rommel J, Westley BR, May FE, Gao J, Meitner PA, Tavares R, Resnick MB: Decreased expression of gastrokine 1 and the trefoil factor interacting protein TFIZ1/GKN2 in gastric cancer: influence of tumor histology and relationship to prognosis. Clin Cancer Res; 2008 Jul 1;14(13):4161-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Decreased GKN1 and GKN2 mRNA expression has been reported in gastric adenocarcinoma.
  • RESULTS: GKN1 was lost in 78% of diffuse and 42% of intestinal cancers (P < 0.0001, diffuse versus intestinal).
  • GKN2 expression was lost in 85% of diffuse and 54% of intestinal type cancers (P < 0.002).
  • Loss of either protein was associated with significantly worse outcome in intestinal-type tumors by univariate analysis; and GKN2 loss remained a predictor of poor outcome in multivariate analysis (P < 0.033).
  • GKN1 and GKN2 loss are associated with shorter overall survival in the intestinal subtype.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Int J Oncol. 2001 Oct;19(4):701-7 [11562744.001]
  • [Cites] Cell. 2002 Apr 5;109(1):113-24 [11955451.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1092-9 [12006524.001]
  • [Cites] Pathology. 2002 Jun;34(3):275-81 [12109791.001]
  • [Cites] Trends Biochem Sci. 2002 Jul;27(7):329-32 [12114016.001]
  • [Cites] Int J Mol Med. 2003 Jul;12(1):3-9 [12792801.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2003 Aug;285(2):G332-43 [12851218.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):592-600 [12894247.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2003 Jul 10;83(13):1166-8 [12921637.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Sep;4(9):721-32 [14506475.001]
  • [Cites] IARC Sci Publ. 2004;(157):327-49 [15055305.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 11;101(19):7409-14 [15123808.001]
  • [Cites] J Pathol. 2004 Jul;203(3):789-97 [15221938.001]
  • [Cites] J Clin Pathol. 2004 Aug;57(8):861-6 [15280409.001]
  • [Cites] Lancet. 1975 Jul 12;2(7924):58-60 [49653.001]
  • [Cites] Gastroenterology. 1991 Jul;101(1):167-74 [2044906.001]
  • [Cites] Br J Cancer. 1991 Oct;64(4):677-82 [1911216.001]
  • [Cites] J Pathol. 1993 Dec;171(4):263-9 [8158455.001]
  • [Cites] Science. 1996 Oct 11;274(5285):259-62 [8824193.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Biochemistry. 2005 Jun 7;44(22):7967-75 [15924415.001]
  • [Cites] Dig Dis Sci. 2005 Jun;50(6):1078-86 [15986858.001]
  • [Cites] Hum Pathol. 2005 Aug;36(8):886-92 [16112005.001]
  • [Cites] Int J Oncol. 2005 Oct;27(4):997-1003 [16142316.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6472-8 [16166422.001]
  • [Cites] Cell Mol Life Sci. 2005 Dec;62(24):2910-5 [16374578.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] Ann Oncol. 2006 Jun;17 Suppl 7:vii97-102 [16760303.001]
  • [Cites] Proteomics. 2006 Aug;6(15):4235-45 [16888721.001]
  • [Cites] Gut. 2006 Dec;55(12):1717-24 [16641130.001]
  • [Cites] Dig Liver Dis. 2007 Feb;39(2):122-9 [17092786.001]
  • [Cites] Gut. 2000 Mar;46(3):312-20 [10673290.001]
  • [Cites] Cancer Lett. 2000 Feb 28;149(1-2):125-34 [10737716.001]
  • [Cites] Jpn J Cancer Res. 2000 May;91(5):459-63 [10835488.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):691-8 [10982763.001]
  • [Cites] J Clin Invest. 2002 Jan;109(2):193-204 [11805131.001]
  • (PMID = 18593995.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR017695-057270; United States / NCI NIH HHS / CA / CA111533-02; United States / NCRR NIH HHS / RR / P20 RR017695; United States / NCRR NIH HHS / RR / RR017695-057270; United States / NCI NIH HHS / CA / R01CA111533; United States / NCRR NIH HHS / RR / P20RR17695; United States / NCI NIH HHS / CA / R01 CA111533-02; United States / NCI NIH HHS / CA / R01 CA111533
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / GKN1 protein, human; 0 / GKN2 protein, human; 0 / Peptide Hormones
  • [Other-IDs] NLM/ NIHMS72349; NLM/ PMC2572195
  •  go-up   go-down


29. Barros-Silva JD, Leitão D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, Bento MJ, Santos L, Ferreira P, Rêgo S, Brandão C, Carneiro F, Lopes C, Schmitt F, Teixeira MR: Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer; 2009 Feb 10;100(3):487-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients.
  • ERBB2 amplification was associated with gastric carcinomas of intestinal type (P=0.007) and with an expansive growth pattern (P=0.021).
  • [MeSH-major] Adenocarcinoma / genetics. Genes, erbB-2. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genomics. 1989 Apr;4(3):362-6 [2565881.001]
  • [Cites] Oncogene. 1989 Jan;4(1):81-8 [2563577.001]
  • [Cites] Hum Pathol. 1990 Mar;21(3):325-32 [2312109.001]
  • [Cites] Mod Pathol. 1992 Jul;5(4):384-90 [1353880.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3942-6 [8099528.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3845-52 [8033105.001]
  • [Cites] Int Surg. 1994 Jan-Mar;79(1):27-32 [8063551.001]
  • [Cites] Oncogene. 1997 Jul 31;15(5):537-47 [9247307.001]
  • [Cites] Lab Invest. 1998 Mar;78(3):345-51 [9520947.001]
  • [Cites] J Gastrointest Surg. 1998 Mar-Apr;2(2):126-31 [9834407.001]
  • [Cites] Cancer. 1999 May 1;85(9):1894-902 [10223227.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2241-51 [10327070.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):255-62 [15517369.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):273-8 [15668283.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Breast Cancer. 2005 Aug;6(3):240-6 [16137435.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1673-84 [16236738.001]
  • [Cites] World J Surg. 2005 Nov;29(11):1422-7; discussion 1428 [16222448.001]
  • [Cites] Gastric Cancer. 2005;8(4):249-52 [16328600.001]
  • [Cites] Dig Dis Sci. 2006 Aug;51(8):1371-9 [16868827.001]
  • [Cites] Mol Syst Biol. 2006;2:54 [17016520.001]
  • [Cites] Cell Oncol. 2006;28(5-6):283-94 [17167181.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1386-93 [17555797.001]
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1059-64 [10533448.001]
  • [Cites] Eur J Cancer. 2000 Feb;36(3):390-6 [10708942.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):16-7 [10973239.001]
  • [Cites] Ann Oncol. 2000 Jul;11(7):837-43 [10997811.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3651-64 [11054438.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):556-62 [11406656.001]
  • [Cites] Acta Oncol. 2001;40(2-3):309-26 [11441938.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1178-80 [11583204.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):84-9 [11823704.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):833-7 [11948459.001]
  • [Cites] World J Gastroenterol. 2002 Dec;8(6):1023-8 [12439918.001]
  • [Cites] J Pathol. 2003 Apr;199(4):418-23 [12635131.001]
  • [Cites] Eur J Surg. 2002;168(11):597-608 [12699095.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):548-53 [14991576.001]
  • [Cites] Cancer. 1977 Jun;39(6):2475-85 [872047.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Dec;81(23):7308-12 [6095284.001]
  • [Cites] Science. 1986 Jun 27;232(4758):1644-6 [3012781.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • (PMID = 19156142.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2658544
  •  go-up   go-down


30. Yamashita H, Kitayama J, Shida D, Ishikawa M, Hama K, Aoki J, Arai H, Nagawa H: Differential expression of lysophosphatidic acid receptor-2 in intestinal and diffuse type gastric cancer. J Surg Oncol; 2006 Jan 1;93(1):30-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of lysophosphatidic acid receptor-2 in intestinal and diffuse type gastric cancer.
  • Recently, it was reported that malignant transformation resulted in aberrant expression of LPA2 in a various type of cancer, suggesting the positive role of LPA2 in tumor development.
  • RESULTS: LPA2 was preferentially expressed (67%) in intestinal-type cancer that was significantly higher than that in diffuse-type cancer (32%, P < 0.0001).
  • The expression of LPA2 showed correlation with a higher rate of lymphatic and venous invasion, lymphatic metastasis, and resultingly tumor stage in diffuse-type cancer, but not in intestinal-type cancer.
  • CONCLUSIONS: Our results highlight the possibility that LPA2 expression is an important process in the carcinogenesis of gastric cancer, especially in intestinal-type cancer.
  • Since LPA can transactivate HGF receptor (c-Met) as well as EGF-receptor, LPA may promote the progression of gastric cancer in diffuse-type with high expression of c-Met.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Female. Gastrectomy. Humans. Immunohistochemistry. Liver Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness


36. Saad RS, Ismiil N, Dubé V, Nofech-Mozes S, Khalifa MA: CDX-2 expression is a common event in primary intestinal-type endocervical adenocarcinoma. Am J Clin Pathol; 2009 Oct;132(4):531-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDX-2 expression is a common event in primary intestinal-type endocervical adenocarcinoma.
  • We studied the expression of cytokeratin (CK) 7, CK20, CDX-2, and p16 in 119 cervical adenocarcinomas (65 usual type [50 invasive; 15 in situ], 37 intestinal type [21 invasive; 16 in situ], 10 endometrioid, 5 adenosquamous, and 2 signet-ring carcinomas) in comparison with 55 cases of rectal adenocarcinomas.
  • CDX-2 was expressed in all cases of rectal adenocarcinoma and in 46 cervical adenocarcinomas (38.7%): usual type, 10 (15%); intestinal type, 31 (84%); endometrioid type, 5 (50%); adenosquamous and signet-ring types, 0 (0%).
  • CDX-2 is a marker for intestinal differentiation irrespective of a rectal or cervical origin.
  • [MeSH-major] Adenocarcinoma / physiopathology. Homeodomain Proteins / biosynthesis. Trans-Activators / biosynthesis. Uterine Cervical Neoplasms / physiopathology
  • [MeSH-minor] Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Female. Humans. Intestinal Neoplasms / physiopathology. Keratin-20 / biosynthesis. Keratin-7 / biosynthesis. Rectal Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19762530.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7; 0 / Trans-Activators; 156560-97-3 / Cdx-2-3 protein
  •  go-up   go-down


37. Khayat AS, Guimarães AC, Calcagno DQ, Seabra AD, Lima EM, Leal MF, Faria MH, Rabenhorst SH, Assumpção PP, Demachki S, Smith MA, Burbano RR: Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma. BMC Gastroenterol; 2009;9:55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma.
  • BACKGROUND: This study evaluates the existence of numerical alterations of chromosome 17 and TP53 gene deletion in gastric adenocarcinoma.
  • The frequency of cells with two chr17 and one TP53 signals observed was higher in diffuse than in intestinal-type GC.
  • Immunoreactivity of p53 was found only in intestinal-type samples.
  • The frequency of cells with two chr17 and two TP53 signals found was higher in samples with positive p53 expression than in negative cases in intestinal-type GC.
  • CONCLUSION: We suggest that TP53 deletion and chromosome 17 aneusomy is a common event in GC and other TP53 alterations, as mutation, may be implicated in the distinct carcinogenesis process of diffuse and intestinal types.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 17 / genetics. Gene Deletion. Gene Expression Regulation, Neoplastic / genetics. Stomach Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Chromosome 17, Deletion.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Sep;37(3):241-9 [10971700.001]
  • [Cites] Cancer Genet Cytogenet. 2009 Apr 1;190(1):1-7 [19264226.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):258-70 [12619111.001]
  • [Cites] Acta Biochim Pol. 2003;50(1):231-8 [12673364.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1311-20 [13679439.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):155-9 [15015591.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Sep;153(2):127-32 [15350302.001]
  • [Cites] Mod Pathol. 2004 Nov;17(11):1328-37 [15154013.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 May;83(9):2934-8 [3458254.001]
  • [Cites] Cancer Genet Cytogenet. 1986 Aug;22(4):295-307 [3731046.001]
  • [Cites] Cancer Genet Cytogenet. 1987 Jan;24(1):63-73 [3791173.001]
  • [Cites] Histochemistry. 1988;89(4):307-16 [3410743.001]
  • [Cites] Cancer. 1990 Aug 1;66(3):491-7 [2364362.001]
  • [Cites] Virchows Arch. 1995;426(5):447-55 [7633655.001]
  • [Cites] Int J Cancer. 1996 May 29;66(5):594-9 [8647618.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):720-6 [8625172.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7081-4 [8692948.001]
  • [Cites] Am J Pathol. 1996 Nov;149(5):1575-84 [8909247.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Dec;92(2):122-9 [8976368.001]
  • [Cites] Nihon Ika Daigaku Zasshi. 1997 Feb;64(1):22-9 [9119949.001]
  • [Cites] Oncology. 1997 Mar-Apr;54(2):166-70 [9075790.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Apr 1;102(1):88-90 [9530349.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] Am J Phys Anthropol. 1999 Jun;109(2):175-80 [10378456.001]
  • [Cites] J Int Med Res. 1999 Mar-Apr;27(2):85-9 [10446695.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2005 Apr;40(4):467-70 [15795596.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 10;331(3):694-700 [15865924.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1759-66 [15827559.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6B):4069-74 [16309200.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Aug;169(1):45-9 [16875936.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4B):2909-14 [16886612.001]
  • [Cites] World J Gastroenterol. 2006 Oct 14;12(38):6207-11 [17036397.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3139-46 [10955795.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Aug;121(1):38-43 [10958939.001]
  • [Cites] Clin Exp Med. 2006 Oct;6(3):129-33 [17061062.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1154-60 [16855375.001]
  • [Cites] Arq Gastroenterol. 2006 Jul-Sep;43(3):247-51 [17160244.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):13-8 [18091326.001]
  • [Cites] Cancer Lett. 2008 Aug 8;266(2):99-115 [18381231.001]
  • [Cites] Lab Invest. 2000 Oct;80(10):1501-8 [11045566.001]
  • (PMID = 19619279.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2716360
  •  go-up   go-down


38. Kushima R, Vieth M, Borchard F, Stolte M, Mukaisho K, Hattori T: Gastric-type well-differentiated adenocarcinoma and pyloric gland adenoma of the stomach. Gastric Cancer; 2006;9(3):177-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric-type well-differentiated adenocarcinoma and pyloric gland adenoma of the stomach.
  • Since 1985, when gastric-type well-differentiated adenocarcinomas were demonstrated in hyperplastic polyps of the stomach, we have studied phenotypic expression in gastrointestinal epithelial lesions.
  • The disease entity of gastric-type well-differentiated adenocarcinoma has recently been accepted, especially in Japan and Europe.
  • Even under these circumstances, the term "gastric adenoma" usually means flat adenoma of the intestinal type.
  • Gastric-type adenomas have been regarded as exceptional until recently.
  • Although gastric-type adenomas could theoretically be classified into foveolar type and pyloric-gland type, foveolar-type adenoma is, in practice, difficult to distinguish from gastric-foveolar-type adenocarcinoma.
  • In this article, we review and discuss the clinicopathological and molecular pathological aspects of gastric-type well-differentiated adenocarcinomas and pyloric gland adenomas, mainly based on our published and unpublished data.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Gastric Mucosa / pathology. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2001;61(1):1-9 [11474241.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):80-6 [11823976.001]
  • [Cites] Pathologe. 2001 Jan;22(1):44-55 [11225445.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):786-95 [12920223.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):166-70 [11668493.001]
  • [Cites] Pathol Int. 2004 Nov;54(11):854-60 [15533229.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1995 Apr;92(4):761-8 [7739127.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):77-82 [9916921.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S37-43 [7762738.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):737-40 [11920644.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] J Clin Pathol. 1985 Jun;38(6):622-30 [4008664.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18327-36 [11278439.001]
  • [Cites] Virchows Arch. 2005 May;446(5):542-5 [15838648.001]
  • [Cites] Oncol Rep. 2001 Jan-Feb;8(1):17-26 [11115563.001]
  • [Cites] Virchows Arch. 2003 Apr;442(4):317-21 [12715167.001]
  • [Cites] Virchows Arch. 2002 Feb;440(2):205-8 [11964052.001]
  • [Cites] Virchows Arch. 2005 May;446(5):537-41 [15838649.001]
  • [Cites] Acta Pathol Jpn. 1982;32 Suppl 2:329-47 [6765003.001]
  • [Cites] Virchows Arch. 1999 Oct;435(4):452-7 [10526011.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1003-7 [10070955.001]
  • [Cites] Gan. 1968 Jun;59(3):251-8 [5726267.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1276-85 [12360042.001]
  • [Cites] Pathol Int. 1996 Nov;46(11):908-17 [8970203.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;120(1-2):103-11 [7903667.001]
  • [Cites] Verh Dtsch Ges Pathol. 2000;84:50-61 [11217449.001]
  • [Cites] Pathol Int. 2004 May;54(5):311-21 [15086835.001]
  • [Cites] Acta Pathol Jpn. 1990 Jul;40(7):494-504 [2220396.001]
  • [Cites] Crit Rev Oncol Hematol. 1994 Dec;17(3):153-80 [7865137.001]
  • [Cites] J Natl Cancer Inst. 1991 May 1;83(9):640-3 [2023282.001]
  • [Cites] Pathol Res Pract. 1996 Sep;192(9):963-9; discussion 970-1 [8950764.001]
  • (PMID = 16952035.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 42
  •  go-up   go-down


39. Macchini F, Fava G, Selicorni A, Torricelli M, Leva E, Valadè A: Barrett's esophagus and Cornelia de Lange Syndrome. Acta Paediatr; 2010 Sep;99(9):1407-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BE was diagnosed in case of replacement of oesophageal mucosa by specialized intestinal-type columnar mucosa.
  • A short segment BE was observed in three patients, a long one in two patients and an infiltrating adenocarcinoma of the lower oesophagus in one patient.
  • A delayed diagnosis because of atypical GERD symptoms and an altered intestinal motility as a result of neurological impairment can be recognized as the main cause.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Author(s)/Journal Compilation © 2010 Foundation Acta Paediatrica.
  • (PMID = 20456260.001).
  • [ISSN] 1651-2227
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


40. Yousem SA: Pulmonary intestinal-type adenocarcinoma does not show enteric differentiation by immunohistochemical study. Mod Pathol; 2005 Jun;18(6):816-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary intestinal-type adenocarcinoma does not show enteric differentiation by immunohistochemical study.
  • Six cases of an unusual variant of primary pulmonary adenocarcinoma resembling colorectal and sinonasal adenocarcinoma are presented.
  • Pulmonary intestinal-type adenocarcinoma occurs in elderly Caucasians and is associated with a histology characteristic of colorectal/enteric adenocarcinoma: a garland-like architecture with a 'gland in gland' periphery, central 'dirty' necrosis, and elongated stratified columnar cells, lacking significant goblet or signet ring differentiation.
  • While a resemblance to intestinal adenocarcinoma by light microscopy is present, immunohistochemical studies comparing these carcinomas with metastatic colorectal adenocarcinoma clearly show a respiratory phenotype with the neoplastic cells expressing thyroid transcription factor-1 and cytokeratin 7 to the exclusion of cytokeratin 20, and failing to express CDX-2.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15605076.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucins; 0 / Nuclear Proteins; 0 / Trans-Activators; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 156560-97-3 / Cdx-2-3 protein; 68238-35-7 / Keratins
  •  go-up   go-down


41. Morris LE, Bloom GS, Frierson HF Jr, Powell SM: Nucleotide variants within the IQGAP1 gene in diffuse-type gastric cancers. Genes Chromosomes Cancer; 2005 Mar;42(3):280-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nucleotide variants within the IQGAP1 gene in diffuse-type gastric cancers.
  • The histopathologic appearance of diffuse gastric carcinoma is defined by non- or poorly cohesive tumor cells, indicating abnormal intercellular adhesion.
  • Many intronic IQGAP1 gene changes were observed, and several occurred more frequently in diffuse-type gastric cancers than in intestinal-type gastric cancers.
  • The most expanded six-repeat sequence was present exclusively in diffuse-type gastric cancers.
  • Additionally, 19 diffuse cases and two intestinal cases exhibited silent coding region nucleotide alterations.
  • Taken together, our results suggest that IQGAP1 coding sequence mutations are not a frequent event in gastric cancer, but do occur in a subset of diffuse-type gastric carcinomas.
  • [MeSH-major] Genetic Variation. Intestinal Neoplasms / genetics. Mutation / genetics. Stomach Neoplasms / genetics. ras GTPase-Activating Proteins / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Animals. Humans. Introns / genetics. Mice. Mice, SCID. Stomach / metabolism. Stomach / pathology. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15611933.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA67900; United States / NINDS NIH HHS / NS / NS530485
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IQ motif containing GTPase activating protein 1; 0 / ras GTPase-Activating Proteins
  •  go-up   go-down


42. Kim DH, Kim JW, Cho JH, Baek SH, Kakar S, Kim GE, Sleisenger MH, Kim YS: Expression of mucin core proteins, trefoil factors, APC and p21 in subsets of colorectal polyps and cancers suggests a distinct pathway of pathogenesis of mucinous carcinoma of the colorectum. Int J Oncol; 2005 Oct;27(4):957-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of mucin core proteins, trefoil factors, APC and p21 in subsets of colorectal polyps and cancers suggests a distinct pathway of pathogenesis of mucinous carcinoma of the colorectum.
  • Mucin core proteins are expressed in a tissue and cell type specific manner in the normal gastrointestinal tract.
  • A higher frequency of ectopic expression of gastric foveolar mucin, MUC5AC, and the expression of intestinal goblet cell mucins, MUC2, was observed respectively in HP (100%, 100%), SA (85%, 85%), TVA (85%, 85%), and VA (100%, 100%), compared to TA (32%, p<0.002; 36%, p<0.01).
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Adenomatous Polyposis Coli Protein / biosynthesis. Colorectal Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Mucins / chemistry. Peptides / metabolism. Proto-Oncogene Proteins p21(ras) / biosynthesis. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142311.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-2; 0 / Mucins; 0 / Peptides; 0 / TFF1 protein, human; 0 / TFF3 protein, human; 0 / Tumor Suppressor Proteins; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


43. Meyer SE, Waltz SE, Goss KH: The Ron receptor tyrosine kinase is not required for adenoma formation in Apc(Min/+) mice. Mol Carcinog; 2009 Nov;48(11):995-1004
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increased Ron expression positively correlates with tumor progression, and reduction of Ron levels in human colon adenocarcinoma cells reverses their tumorigenic properties.
  • To understand the role of Ron in early stage intestinal tumorigenesis, we generated Apc-mutant (Apc(Min/+)) mice with and without Ron signaling.
  • Interestingly, we report here that significantly more Apc(Min/+) Ron-deficient mice developed higher tumor burden than Apc(Min/+) mice with wild-type Ron.
  • Even though baseline levels of intestinal crypt proliferation were increased in the Apc(Min/+) Ron-deficient mice, loss of Ron did not influence tumor size or histological appearance of the Apc(Min/+) adenomas, nor was beta-catenin localization changed compared to Apc(Min/+) mice with Ron.
  • Together, these data suggest that Ron may be important in normal intestinal tissue homeostasis, but that the expression of this receptor is not required for the formation and growth of adenomas in Apc(Min/+) mice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1999 Nov 1;18(21):5931-42 [10545105.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1784-7 [9065401.001]
  • [Cites] Exp Cell Res. 2000 Nov 25;261(1):229-38 [11082293.001]
  • [Cites] Dig Dis Sci. 2001 Feb;46(2):424-9 [11281194.001]
  • [Cites] Nat Genet. 2001 Jun;28(2):155-9 [11381263.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5010-5 [11431334.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):5857-68 [11486025.001]
  • [Cites] J Clin Invest. 2001 Aug;108(4):567-76 [11518730.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8357-60 [11731407.001]
  • [Cites] Genome Res. 2002 Jan;12(1):88-97 [11779834.001]
  • [Cites] Cancer Lett. 2002 Sep 8;183(1):31-41 [12049812.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2051-3 [12242442.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38104-10 [12177064.001]
  • [Cites] Hepatology. 2002 Nov;36(5):1053-60 [12395314.001]
  • [Cites] Oncogene. 2003 Jan 16;22(2):186-97 [12527888.001]
  • [Cites] Curr Cancer Drug Targets. 2003 Feb;3(1):31-40 [12570659.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):762-77 [12612914.001]
  • [Cites] Carcinogenesis. 2003 Aug;24(8):1291-300 [12807733.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3694-700 [15150130.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] J Cell Biol. 1992 Mar;116(6):1517-26 [1541640.001]
  • [Cites] Science. 1992 May 1;256(5057):668-70 [1350108.001]
  • [Cites] Nature. 1992 Sep 17;359(6392):235-7 [1528264.001]
  • [Cites] Oncogene. 1999 May 6;18(18):2883-91 [10362259.001]
  • [Cites] Int J Oncol. 1999 Oct;15(4):709-14 [10493952.001]
  • [Cites] Oncogene. 2004 Nov 4;23(52):8464-74 [15378025.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):27-36 [15447977.001]
  • [Cites] Virchows Arch. 1997 Sep;431(3):167-72 [9334837.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1087-9 [9515784.001]
  • [Cites] Carcinogenesis. 1998 Apr;19(4):543-9 [9600336.001]
  • [Cites] Exp Lung Res. 1998 Jul-Aug;24(4):437-53 [9659576.001]
  • [Cites] Genes Funct. 1997 Feb;1(1):69-83 [9680329.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Int J Cancer. 1998 Nov 23;78(5):629-35 [9808534.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1399-405 [10188882.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Oncogene. 2005 Jan 13;24(3):479-88 [15531916.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1285-93 [15735014.001]
  • [Cites] Ann Surg Oncol. 2005 Apr;12(4):273-81 [15827676.001]
  • [Cites] Acta Pharmacol Sin. 2006 Jun;27(6):641-50 [16723080.001]
  • [Cites] Cancer Sci. 2006 Aug;97(8):710-5 [16863504.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8430-8 [16951153.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9162-70 [16982759.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11967-74 [17178895.001]
  • [Cites] Genetics. 2007 Jun;176(2):1237-44 [17435219.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6075-82 [17616662.001]
  • [Cites] Future Oncol. 2007 Aug;3(4):441-8 [17661719.001]
  • [Cites] J Pathol. 2007 Dec;213(4):402-11 [17955509.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6680-7 [18701492.001]
  • [Cites] Oncogene. 1993 May;8(5):1195-202 [8386824.001]
  • [Cites] Hum Mol Genet. 1992 Sep;1(6):387-90 [1338760.001]
  • [Cites] J Cell Biol. 1993 Nov;123(4):877-93 [8227147.001]
  • [Cites] Biochim Biophys Acta. 1993 Dec 23;1155(3):357-71 [8268192.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5953-8 [7954428.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1061-4 [7576992.001]
  • [Cites] Acta Gastroenterol Belg. 1995 Sep-Dec;58(5-6):433-51 [8776001.001]
  • [Cites] Gastroenterology. 1996 Oct;111(4):1134-40 [8831610.001]
  • [Cites] EMBO J. 1996 Nov 1;15(21):5866-75 [8918464.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1402-7 [9037065.001]
  • [Cites] Scand J Gastroenterol. 2000 May;35(5):534-9 [10868458.001]
  • (PMID = 19452510.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA059268; United States / NCI NIH HHS / CA / R01 CA125379; United States / NCI NIH HHS / CA / CA 100002; United States / NCI NIH HHS / CA / R01 CA100002; United States / NCI NIH HHS / CA / T32 CA 59268
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; EC 2.7.1.- / RON protein; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  • [Other-IDs] NLM/ NIHMS600186; NLM/ PMC4102426
  •  go-up   go-down


44. Roh YH, Kim YH, Lee HW, Kim SJ, Roh MS, Jeong JS, Jung GJ: The clinicopathologic and immunohistochemical characteristics of ampulla of Vater carcinoma: the intestinal type is associated with a better prognosis. Hepatogastroenterology; 2007 Sep;54(78):1641-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinicopathologic and immunohistochemical characteristics of ampulla of Vater carcinoma: the intestinal type is associated with a better prognosis.
  • BACKGROUND/AIMS: We wanted to compare the clinicopathological parameters with the immunohistochemical expression patterns and patient survival for the intestinal type (IT) and the pancreatobiliary type (PT) of ampulla of Vater carcinoma.
  • Ampulla of Vater carcinoma can be classified histologically into either IT or PT.
  • The biologic behavior and patient prognosis vary considerably in relation to the tumor type.
  • METHODOLOGY: From September, 1995, to February, 2004, 34 patients with the pathologic diagnosis of ampulla of Vater carcinoma were retrospectively reviewed and the prognostic factors were analyzed.
  • To classify the phenotypes of the tumors, the keratin types (CK7 and CK20), the type of apomucin of the mucosa (MUC2), and the glucose transporter (GLUT1) were studied for differentiating the tumor types.
  • RESULTS: The 5-year survival rate of the 34 patients with ampulla of Vater carcinoma was 58.8%.
  • A study with a larger number samples would probably elucidate the different clinical course between these two types of ampulla of Vater carcinoma.
  • [MeSH-major] Ampulla of Vater / pathology. Carcinoma / pathology. Common Bile Duct Neoplasms / pathology. Gene Expression Regulation, Neoplastic. Immunohistochemistry / methods
  • [MeSH-minor] Adenocarcinoma / metabolism. Aged. Female. Glucose Transporter Type 1 / biosynthesis. Humans. Keratin-20 / biosynthesis. Keratin-7 / biosynthesis. Lymphatic Metastasis. Male. Middle Aged. Mucin-2. Mucins / biosynthesis. Prognosis. Time Factors. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019683.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Keratin-20; 0 / Keratin-7; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins; 0 / SLC2A1 protein, human
  •  go-up   go-down


45. Bird-Lieberman EL, Lao-Sirieix P, Saeed I, Khoo D, Burnham R, Fitzgerald R: The definition and management of Barrett's oesophagus: a case report, review of the literature and a suggestion for the future. BMJ Case Rep; 2009;2009
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we describe the case of a 69-year-old female with 10 cm of gastric-type columnar-lined oesophagus confirmed on histochemical staining.
  • Surveillance biopsies, performed according to protocol, revealed an intramucosal adenocarcinoma.
  • The patient was successfully treated with a transhiatal oesophagectomy and a detailed examination of the entire surgical specimen confirmed that the columnar oesophagus was lined by gastric villiform mucosa complicated by intramucosal carcinoma, on the background of dysplasia with no intestinal metaplasia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):333-8 [10930368.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1188-93 [11688579.001]
  • [Cites] Gut. 2002 Sep;51(3):316-22 [12171950.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):534-5 [12958113.001]
  • [Cites] Thorax. 1953 Jun;8(2):87-101 [13077502.001]
  • [Cites] Gut. 2004 Aug;53(8):1070-4 [15247170.001]
  • [Cites] Gut. 2005 Mar;54 Suppl 1:i6-12 [15711008.001]
  • [Cites] Gut. 2006 Apr;55(4):442 [16531521.001]
  • [Cites] Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943 [16928254.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] Am J Gastroenterol. 2008 Nov;103(11):2694-9 [18853967.001]
  • [Cites] Am J Clin Pathol. 1987 Mar;87(3):301-12 [3825997.001]
  • [Cites] Ann Surg. 1983 Oct;198(4):554-65 [6625723.001]
  • [Cites] Hum Pathol. 1994 Oct;25(10):982-93 [7927321.001]
  • [Cites] Gastrointest Endosc. 1996 Jul;44(1):91-5 [8836727.001]
  • [Cites] Gastroenterology. 1996 Feb;110(2):614-21 [8566611.001]
  • [Cites] Br J Surg. 1950 Oct;38(150):175-82 [14791960.001]
  • [Cites] Histopathology. 2005 Apr;46(4):361-73 [15810947.001]
  • (PMID = 21686804.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029858
  •  go-up   go-down


46. Lehrbach DM, Cecconello I, Ribeiro Jr U, Capelozzi VL, Ab'saber AM, Alves VA: Adenocarcinoma of the esophagogastric junction: relationship between clinicopathological data and p53, cyclin D1 and Bcl-2 immunoexpressions. Arq Gastroenterol; 2009 Oct-Dec;46(4):315-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the esophagogastric junction: relationship between clinicopathological data and p53, cyclin D1 and Bcl-2 immunoexpressions.
  • CONTEXT: Esophagogastric junction adenocarcinoma has an aggressive behavior, and TNM (UICC) staging is not always accurate enough to categorize patient's outcome.
  • OBJECTIVES: To evaluated p53, cyclin D1 and Bcl-2 immunoexpressions in esophagogastric junction adenocarcinoma patients, without Barrett's esophagus, and to compared to clinicopathological characteristics and survival rate.
  • RESULTS: Fifty (66.7%) of the tumors were intestinal type and 25 (33.3%) were diffuse.


47. Sugai T, Tsukahara M, Endoh M, Shioi Y, Takebe N, Mue Y, Matsushita H, Toyota M, Suzuki K: Analysis of cell cycle-related proteins in gastric intramucosal differentiated-type cancers based on mucin phenotypes: a novel hypothesis of early gastric carcinogenesis based on mucin phenotype. BMC Gastroenterol; 2010;10:55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of cell cycle-related proteins in gastric intramucosal differentiated-type cancers based on mucin phenotypes: a novel hypothesis of early gastric carcinogenesis based on mucin phenotype.
  • Thus, expression patterns of cell cycle-related proteins were investigated in the early phase of differentiated-type gastric cancers to ascertain any mechanistic relationships with mucin phenotypes.
  • METHODS: Immunostaining for Cyclins D1, A, E, and p21, p27, p53 and beta-catenin was used to examine impairments of the cell cycle in 190 gastric intramucosal differentiated-type cancers.
  • RESULTS: Overexpressions of p53, cyclin D1 and cyclin A were significantly more frequent in a gastric phenotype than an intestinal phenotype.
  • Cyclin A was overexpressed in a mixed phenotype compared with an intestinal phenotype, while p27 overexpression was more frequent in an intestinal phenotype than in a mixed phenotype.
  • Reduction of p21 was a common feature of the gastric intramucosal differentiated-type cancers examined.
  • CONCLUSIONS: Our results suggest that the levels of some cell cycle regulators appear to be associated with mucin phenotypes of early gastric differentiated-type cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Cycle Proteins / metabolism. Gastric Mucins / metabolism. Phenotype. Stomach Neoplasms / metabolism
  • [MeSH-minor] Cell Differentiation. Cyclin A / metabolism. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Humans. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Proliferating Cell Nuclear Antigen / metabolism. Tumor Suppressor Protein p53 / metabolism


48. Namikawa T, Hanazaki K: Mucin phenotype of gastric cancer and clinicopathology of gastric-type differentiated adenocarcinoma. World J Gastroenterol; 2010 Oct 7;16(37):4634-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin phenotype of gastric cancer and clinicopathology of gastric-type differentiated adenocarcinoma.
  • Differentiated adenocarcinoma of the stomach is classified into gastric or intestinal phenotypes based on mucus expression.
  • Recent advances in mucin histochemistry and immunohistochemistry have highlighted the importance of such a distinction, and it is important clinically to distinguish between gastric- and intestinal-type differentiated adenocarcinoma.
  • However, a clinical and pathological diagnosis of this type is often difficult in early gastric cancer because of histological similarities between a hyperplastic epithelium and low-grade atypia.
  • It is therefore critical to consider these diagnostic difficulties and different biological behaviors with high malignant potential when treating patients with gastric-type differentiated adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Mucins. Phenotype. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2000 Jul;191(3):257-63 [10878546.001]
  • [Cites] Cancer. 2000 Aug 15;89(4):724-32 [10951333.001]
  • [Cites] Histopathology. 2000 Dec;37(6):513-22 [11122433.001]
  • [Cites] Oncology. 2001;61(3):212-20 [11574777.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1523-30 [11813565.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):80-6 [11823976.001]
  • [Cites] Pathol Int. 2004 May;54(5):311-21 [15086835.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1223-34 [15154009.001]
  • [Cites] Gan. 1968 Jun;59(3):251-8 [5726267.001]
  • [Cites] J Natl Cancer Inst. 1974 Jul;53(1):19-30 [4835098.001]
  • [Cites] Cancer. 1983 Aug 1;52(3):498-503 [6190549.001]
  • [Cites] Acta Pathol Jpn. 1990 Jul;40(7):494-504 [2220396.001]
  • [Cites] Pathol Int. 1999 Jan;49(1):55-61 [10227725.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Gastric Cancer. 2005;8(4):220-7 [16328596.001]
  • [Cites] World J Gastroenterol. 2006 Apr 28;12(16):2510-6 [16688795.001]
  • [Cites] World J Gastroenterol. 2006 Jun 28;12(24):3803-9 [16804962.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6469-79 [17085661.001]
  • [Cites] J Pathol. 1993 Jan;169(1):73-8 [8433217.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;119(5):265-72 [8440743.001]
  • [Cites] Cancer. 1993 Dec 1;72(11):3179-84 [7902202.001]
  • [Cites] Cancer. 1994 Jul 15;74(2):556-64 [8033033.001]
  • [Cites] Gastroenterology. 1997 Aug;113(2):455-64 [9247464.001]
  • (PMID = 20872962.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Mucins
  • [Other-IDs] NLM/ PMC2951512
  •  go-up   go-down


49. He JJ: [Meta analysis of 2025 cases with multiple primary colorectal carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2006 May;9(3):225-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Meta analysis of 2025 cases with multiple primary colorectal carcinoma].
  • OBJECTIVE: To summarize the clinicopathological characteristics of multiple primary colorectal carcinoma.
  • METHOD: With "multiple primary colorectal carcinoma" as search words,and with the same inclusion and exclusion criteria, related Chinese literatures published were retrieved.
  • RESULTS: The incidence of multiple primary colorectal carcinoma was 2.9%; and the average age was 53 years.
  • 55.2% of the cases with synchronous multiple primary colorectal carcinoma were diagnosed by fiberoptic colonoscopy before operation,37.5% by intraoperative exploration, 15.7% by postoperative pathology.
  • 94.8% of the cases with metachronous multiple primary colorectal carcinoma were diagnosed by fiberoptic colonoscopy before operation,and the average interval was 5.2 years.
  • 37.6% of the cases were complicated with extra- intestinal lesions,and 43.7% adenoma or polyps.
  • Histological type was the same in 60.6% of the cases,and adenocarcinoma accounted for 89.2% and cancerization of adenoma 8.4%.
  • The 3, 5, 10 and 15 year survival rates were 64.3%, 44.6%, 26.3% or 9.4% in synchronous multiple primary colorectal carcinoma respectively, and 69.6%, 59.2%, 45.0%, 36.7% in metachronous multiple primary colorectal carcinoma.
  • CONCLUSIONS: Multiple primary colorectal carcinoma is rare in clinic.
  • The prognosis of metachronous multiple primary carcinoma is better than that of synchronous multiple primary colorectal carcinoma.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16721683.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Meta-Analysis
  • [Publication-country] China
  •  go-up   go-down


50. Stelow EB, Mills SE, Jo VY, Carlson DL: Adenocarcinoma of the upper aerodigestive tract. Adv Anat Pathol; 2010 Jul;17(4):262-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the upper aerodigestive tract.
  • Although squamous cell carcinoma is the most frequent malignant diagnosis made with upper aerodigestive tract specimens, a myriad of neoplasms can occur throughout the area.
  • Very uncommonly, one encounters adenocarcinomas that cannot be better classified as salivary gland-type neoplasia.
  • This manuscript reviews these tumors, including sinonasal intestinal-type adenocarcinomas, sinonasal low-grade and high-grade nonintestinal adenocarcinomas and nasopharyngeal papillary adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Respiratory Tract Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20574171.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


51. Zhang S, Gao F, Luo J, Yang J: Prognostic factors in survival of colorectal cancer patients with synchronous liver metastasis. Colorectal Dis; 2010 Aug;12(8):754-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Criteria studied consisted of gender, age, time of symptoms, primary tumour location, primary tumour circumference, histological type, grade (tumour differentiation), T-status, N-status, large bowel obstruction, type of operation, primary tumour resection, ascities, location, number and diameter of liver lesions, preoperative CEA and chemotherapy.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Carcinoembryonic Antigen / blood. Colon / pathology. Colon / surgery. Female. Humans. Intestinal Obstruction / mortality. Intestinal Obstruction / pathology. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Regression Analysis. Retrospective Studies. Risk Factors. Sex Characteristics. Time Factors. Tumor Burden. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19508508.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


52. Palacios E, Rojas R: Sinonasal intestinal-type adenocarcinoma. Ear Nose Throat J; 2006 Sep;85(9):572
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal intestinal-type adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radiography. Nose Neoplasms / radiography. Paranasal Sinus Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17044421.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Sakamoto N, Ohtsubo S, Iguchi A, Takeshita M, Kurozumi T: Intestinal-type mucinous adenocarcinoma arising from the prostatic duct. Int J Urol; 2005 May;12(5):509-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal-type mucinous adenocarcinoma arising from the prostatic duct.
  • We present a case of mucinous adenocarcinoma of intestinal type arising from the prostatic duct in a 72-year-old Japanese man.
  • A transurethral biopsy specimen revealed mucinous adenocarcinoma.
  • The cancer cells resembled the intestinal epithelium rather than either the prostatic duct or the acinar epithelium, which showed diffusely positive immunohistochemical staining for carcinoembryonic antigen, but showed negative staining for prostate-specific antigen.
  • Therefore, these findings suggest mucinous adenocarcinoma of intestinal type arising from the prostatic duct.
  • A number of cases with mucinous adenocarcinoma arising from the prostatic urethra resembling the present case have been reported, but this is the first known case of carcinoma arising from the prostatic duct.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948756.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


54. Basseri B, Conklin JL, Mertens RB, Lo SK, Bellack GS, Shaye OA: Heterotopic gastric mucosa (inlet patch) in a patient with laryngopharyngeal reflux (LPR) and laryngeal carcinoma: a case report and review of literature. Dis Esophagus; 2009;22(4):E1-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterotopic gastric mucosa (inlet patch) in a patient with laryngopharyngeal reflux (LPR) and laryngeal carcinoma: a case report and review of literature.
  • Esophageal and supraesophageal symptoms are commonly associated with inlet patch, while esophageal adenocarcinoma rarely complicates it.
  • Laryngeal adenocarcinoma associated with inlet patch is not described in the literature.
  • Herein, we present the first reported case of inlet patch associated with laryngeal carcinoma.
  • Biopsies showed columnar mucosa (predominantly gastric cardiac/fundic type) consistent with inlet patch, with focal intestinal metaplasia.

  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473208.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


55. Catassi C, Bearzi I, Holmes GK: Association of celiac disease and intestinal lymphomas and other cancers. Gastroenterology; 2005 Apr;128(4 Suppl 1):S79-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of celiac disease and intestinal lymphomas and other cancers.
  • Celiac disease (CD) is associated with intestinal lymphoma and other forms of cancer, especially adenocarcinoma of the small intestine, of the pharynx, and of the esophagus.
  • Recent studies indicated that (1) CD is associated with a significantly increased risk for NHL, especially of the T-cell type and primarily localized in the gut (EATL);.
  • [MeSH-major] Adenocarcinoma / etiology. Celiac Disease / complications. Gastrointestinal Neoplasms / etiology. Intestinal Neoplasms / etiology. Lymphoma, T-Cell / etiology

  • Genetic Alliance. consumer health - Celiac Disease.
  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. GLUTEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15825131.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 8002-80-0 / Glutens
  • [Number-of-references] 40
  •  go-up   go-down


56. Sato F, Meltzer SJ: CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer; 2006 Feb 1;106(3):483-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The upper gastrointestinal (GI) cancers have various carcinogenic pathways and precursor lesions, such as dysplasia for esophageal squamous cell carcinoma, Barrett esophagus for esophageal adenocarcinoma, and intestinal metaplasia for the intestinal-type of gastric cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. CpG Islands / genetics. Esophageal Neoplasms / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 American Cancer Society.
  • [ErratumIn] Cancer. 2006 Apr 1;106(7):1641
  • (PMID = 16362978.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 138
  •  go-up   go-down


57. González CA, Pera G, Agudo A, Bueno-de-Mesquita HB, Ceroti M, Boeing H, Schulz M, Del Giudice G, Plebani M, Carneiro F, Berrino F, Sacerdote C, Tumino R, Panico S, Berglund G, Simán H, Hallmans G, Stenling R, Martinez C, Dorronsoro M, Barricarte A, Navarro C, Quiros JR, Allen N, Key TJ, Bingham S, Day NE, Linseisen J, Nagel G, Overvad K, Jensen MK, Olsen A, Tjønneland A, Büchner FL, Peeters PH, Numans ME, Clavel-Chapelon F, Boutron-Ruault MC, Roukos D, Trichopoulou A, Psaltopoulou T, Lund E, Casagrande C, Slimani N, Jenab M, Riboli E: Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Int J Cancer; 2006 May 15;118(10):2559-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST).
  • No evidence exists from cohort studies about adenocarcinoma of oesophagus (ACO).
  • We observed no association with total vegetable intake or specific groups of vegetables and GC risk, except for the intestinal type, where a negative association is possible regarding total vegetable (calibrated HR 0.66; 95% CI 0.35-1.22 per 100 g increase) and onion and garlic intake (calibrated HR 0.70; 95% CI 0.38-1.29 per 10 g increase).
  • Our study supports a possible protective role of vegetable intake in the intestinal type of GC and the ACO.
  • [MeSH-major] Adenocarcinoma / prevention & control. Esophageal Neoplasms / prevention & control. Fruit. Stomach Neoplasms / prevention & control. Vegetables

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • [CommentIn] Int J Cancer. 2006 Dec 15;119(12):2991; author reply 2992 [17016826.001]
  • (PMID = 16380980.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


58. Li GH, Qian W, Song GQ, Hou XH: Effect of vasoactive intestinal peptide on gastric adenocarcinoma. J Gastroenterol Hepatol; 2007 Aug;22(8):1328-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of vasoactive intestinal peptide on gastric adenocarcinoma.
  • BACKGROUND AND AIM: Vasoactive intestinal peptide (VIP) is a gastrointestinal hormone in the secretin-VIP family.
  • However, the effect of VIP on gastric adenocarcinoma is not clear yet.
  • The aim of the present study was to investigate the effect of VIP on gastric adenocarcinoma, especially autocrine regulation of VIP on gastric adenocarcinoma.
  • METHODS: VIP mRNA and protein, and its receptor mRNA (VIPR(1) and VIPR(2)) were measured in 15 normal antrum mucosa, 20 gastric adenocarcinoma tissues, and the SGC7901 gastric adenocarcinoma cell line by using reverse transcription polymerase chain reaction (RT-PCR), immunohistochemistry, or radioimmunoassay methods.
  • RESULTS: The VIP mRNA expression in gastric adenocarcinoma tissues was significantly higher than that in normal antrum mucosa (P < 0.01).
  • The VIP-positive immunoreactivity cells existed in 40% of gastric adenocarcinoma tissues, but not in normal tissues (P < 0.01).
  • The VIP-positive immunoreactivity nerve fibers were observed in normal tissues, but not in adenocarcinoma tissues (P < 0.01).
  • The expression rate of VIPR(1) mRNA in adenocarcinoma tissues was significantly lower than that in normal tissues, but that of VIPR(2) mRNA in the two kinds of tissues were similar (P > 0.05).
  • In addition, the expression quantity of VIPR(1) mRNA and VIPR(2) mRNA in adenocarcinoma tissues was significantly lower than that in normal tissues (P < 0.05).
  • CONCLUSIONS: The expression of VIP mRNA upregulates, but the expressions of VIPR mRNA downregulates in gastric adenocarcinoma tissues.
  • The gastric adenocarcinoma tissues contain endocrine cells to secrete VIP, which show malignant specialities.
  • [MeSH-major] Adenocarcinoma / metabolism. Stomach Neoplasms / metabolism. Vasoactive Intestinal Peptide / physiology
  • [MeSH-minor] Adolescent. Adult. Cell Line, Tumor. Cell Proliferation / drug effects. Female. Humans. Immunohistochemistry. Male. Middle Aged. Ornithine Decarboxylase / metabolism. Proto-Oncogene Proteins c-myb / metabolism. RNA, Messenger / metabolism. Receptors, Vasoactive Intestinal Polypeptide, Type I. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17559364.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myb; 0 / RNA, Messenger; 0 / Receptors, Vasoactive Intestinal Polypeptide, Type I; 37221-79-7 / Vasoactive Intestinal Peptide; EC 4.1.1.17 / Ornithine Decarboxylase
  •  go-up   go-down


59. Georgescu SO, Neacşu CN, Vintilă D, Popa P, Florea N, Mihailovici MS: The histopathologic type of the periampullary tumors. Is it important for survival? Chirurgia (Bucur); 2009 Nov-Dec;104(6):697-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The histopathologic type of the periampullary tumors. Is it important for survival?
  • The tumors of this region are named periampullary adenocarcinomas, but the histologic type of these malignancies seems to have an important significance for survival.
  • AIM: Our purpose is to determine whether the histologic type of the resectable vaterian adenocarcinomas is a prognostic factor.
  • Using our database we assessed the overall survival based on histologic type, tumor stage, lymph nodes involvement, tumor size and the level of differentiation.
  • RESULTS: The histologic type of the adenocarcinomas was intestinal in 23 cases (60.5%) and pancreatobiliary in 15 cases (39.5%).
  • The median overall survival was significantly higher in patients with well differentiate intestinal-type in T1-T2 stage without nodes involvement.
  • CONCLUSION: The intestinal type of periampullary adenocarcinomas has a long survival, but the lymph nodes involvement and the lower degree of differentiation are associated with a high risk of death in these malignancies.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Ampulla of Vater. Duodenal Neoplasms / mortality. Duodenal Neoplasms / pathology. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / pathology


60. Sanada Y, Hirose Y, Osada S, Tanaka Y, Takahashi T, Yamaguchi K, Yoshida K: Immunohistochemical study of claudin 18 involvement in intestinal differentiation during the progression of intraductal papillary mucinous neoplasm. Anticancer Res; 2010 Jul;30(7):2995-3003
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical study of claudin 18 involvement in intestinal differentiation during the progression of intraductal papillary mucinous neoplasm.
  • BACKGROUND AND AIM: A comparison was made between pancreatic ductal adenocarcinoma (PDAC), pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous carcinoma (IPMC) in order to understand the association between several markers and malignant potential.
  • P53 was positively stained in one of the 4 IPMCs in which minimally invasive tubular type carcinomas were observed.
  • CLDN18 was specifically expressed in intestinal-type components of IPMCs.
  • CONCLUSION: CLDN18 is involved in intestinal-type epithelial differentiation in the progression of IPMCs, contradicting the previous knowledge of its specificity in gastric epithelial differentiation.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / metabolism. Membrane Proteins / metabolism. Pancreatic Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cell Differentiation / physiology. Claudins. Disease Progression. Humans. Immunohistochemistry. Intestines / pathology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683045.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / CLDN18 protein, human; 0 / Claudins; 0 / Membrane Proteins
  •  go-up   go-down


61. Kazakov DV, Suster S, LeBoit PE, Calonje E, Bisceglia M, Kutzner H, Rütten A, Mentzel T, Schaller J, Zelger B, Baltaci M, Leivo I, Rose C, Fukunaga M, Simpson RH, Yang Y, Carlson JA, Cavazza A, Hes O, Mukensnabl P, Vanecek T, Fidalgo A, Pizinger K, Michal M: Mucinous carcinoma of the skin, primary, and secondary: a clinicopathologic study of 63 cases with emphasis on the morphologic spectrum of primary cutaneous forms: homologies with mucinous lesions in the breast. Am J Surg Pathol; 2005 Jun;29(6):764-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous carcinoma of the skin, primary, and secondary: a clinicopathologic study of 63 cases with emphasis on the morphologic spectrum of primary cutaneous forms: homologies with mucinous lesions in the breast.
  • We present the largest series of mucinous carcinoma involving the skin, describing the histopathologic, immunohistochemical, electron microscopic, and cytogenetic findings.
  • We demonstrate that primary cutaneous mucinous carcinomas span a morphologic spectrum compatible to their mammary counterparts.
  • Most lesions seem to originate from in situ lesions that may represent, using mammary pathology terminology, ductal hyperplasia, atypical ductal hyperplasia, or ductal carcinoma in situ or a combination of the three.
  • Mammary mucinous carcinoma involving the skin: all patients presented with lesions on chest wall, breast, axilla, and these locations can serve as clue to the breast origin.
  • Microscopically, cutaneous lesions were of both pure and mixed type, and this correlated with the primary in the breast.
  • Dirty necrosis was a constant histologic finding in intestine mucinous carcinomas involving the skin, and this feature may serve as a clue to an intestinal origin.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Intestinal Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897743.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Gologan A, Acquafondata M, Dhir R, Sepulveda AR: Polymeric immunoglobulin receptor-negative tumors represent a more aggressive type of adenocarcinomas of distal esophagus and gastroesophageal junction. Arch Pathol Lab Med; 2008 Aug;132(8):1295-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymeric immunoglobulin receptor-negative tumors represent a more aggressive type of adenocarcinomas of distal esophagus and gastroesophageal junction.
  • CONTEXT: Polymeric immunoglobulin receptor (PIgR) expression has been found in gastric mucosa and gastric cancers, but it is not known whether PIgR expression is related to background intestinal metaplasia nor the patterns of PIgR expression in tumors arising in the distal esophagus and gastroesophageal (GE) junction.
  • OBJECTIVES: To identify clinicopathologic features of tumors associated with PIgR expression and to determine whether PIgR expression is associated with intestinal differentiation of tumors and intestinal metaplasia in background mucosa in 3 groups of upper gastrointestinal adenocarcinomas.
  • These groups are (1) gastric adenocarcinomas, (2) adenocarcinomas of the distal esophagus and GE junction with background intestinal metaplasia, and (3) adenocarcinomas of the distal esophagus and GE junction without background intestinal metaplasia.
  • DESIGN: Expression of PIgR and CDX2 in nonneoplastic mucosa, intestinal metaplasia, and adenocarcinomas was examined by immunohistochemistry in 42 cases: 14 gastric and 28 from the distal esophagus and GE junction, including 13 with esophageal or GE junction intestinal metaplasia.
  • RESULTS: PIgR and CDX2 were expressed in all cases of intestinal metaplasia.
  • CONCLUSIONS: PIgR is uniformly expressed in intestinal metaplasia and in a subgroup of adenocarcinomas of the distal esophagus, GE junction, and stomach.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction. Intestines / pathology. Receptors, Polymeric Immunoglobulin / analysis. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18684029.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Receptors, Polymeric Immunoglobulin
  •  go-up   go-down


63. Ismail HM, Moneer M, El-Baradie M, Khorshid O, Touny A: Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray. J Egypt Natl Canc Inst; 2007 Jun;19(2):147-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray.
  • BACKGROUND: The aim of the study was to verify the frequency of the immunohistochemical overexpression of her-2/neu and p53 in gastric carcinoma and their relation to the other clinico-pathological features and the impact on survival rates.
  • PATIENTS AND METHODS: A total of 93 patients of gastric carcinoma, who had a potential curative surgery in the period from 2001-2007 and with representative paraffin blocks, and sufficient follow-up data were included in this study.
  • None of the examined clinico-pathologic factors had a significant relation to her-2/neu overexpression. p53 was overexpressed in intestinal type, 14/34 (41.2%), more than in diffuse type, 10/59 (16.9%), (p= 0.01).
  • CONCLUSION: Although, this study failed to show any prognostic effect of p53 and her-2/neu on survival rates, we may suggest that p53 overexpression may play a role in the pathogenesis of intestinal gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / therapy. Adenocarcinoma, Mucinous / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / therapy. Receptor, ErbB-2 / metabolism. Stomach Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19034345.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


64. Calcagno DQ, Leal MF, Taken SS, Assumpção PP, Demachki S, Smith Mde A, Burbano RR: Aneuploidy of chromosome 8 and C-MYC amplification in individuals from northern Brazil with gastric adenocarcinoma. Anticancer Res; 2005 Nov-Dec;25(6B):4069-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aneuploidy of chromosome 8 and C-MYC amplification in individuals from northern Brazil with gastric adenocarcinoma.
  • BACKGROUND: Gastric cancer is the third most frequent type of neoplasia.
  • In northern Brazil, the State of Pará has a high incidence of this type of neoplasia.
  • RESULTS: All cases showed aneuploidy of chromosome 8 and C-MYC amplification, in both the diffuse and the intestinal histopathological types of Laurén.
  • C-MYC amplification, like homogeneously-stained regions (HSRs) and double minutes (DMs), was observed only in the intestinal-type.
  • Translocation of C-MYC was observed only in the diffuse-type.
  • CONCLUSION: Chromosome 8 can be used as a marker in the diagnosis of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Aneuploidy. Chromosomes, Human, Pair 8 / genetics. Genes, myc / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Anticancer Res. 2006 Jan-Feb;26(1a):445
  • (PMID = 16309200.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


65. DeMeester SR: Re: Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum Pathol; 2009 Aug;40(8):1208-9; author reply 1209-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re: Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Cardia / pathology. Esophageal Neoplasms / diagnosis. Intestines / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Hum Pathol. 2009 Jan;40(1):65-74 [18755496.001]
  • (PMID = 19616700.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


66. Clemente G, Sarno G, Giordano M, De Rose AM, Giovannini I, Vecchio FM, Nuzzo G: Total gastrectomy for type 1 gastric carcinoid: an unusual surgical indication? Minerva Chir; 2007 Oct;62(5):421-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total gastrectomy for type 1 gastric carcinoid: an unusual surgical indication?
  • Gastric carcinoid is a relatively rare neoplasm with peculiar features which differentiate it from the intestinal and pulmonary carcinoid and, obviously, from gastric adenocarcinoma.
  • Gastric carcinoids are divided into three different types: Type 1, associated with gastric atrophy and megaloblastic anemia; Type 2, associated with Zollinger-Ellison syndrome within a type 1 multiple endocrine neoplasia (MEN); and Type 3, sporadic tumor not associated with other lesions, particularly invasive and with poor prognosis.
  • Type 1 carcinoid is usually asymptomatic and casually detected at endoscopy due to aspecific symptoms or to screening in patients with atrophic gastritis.
  • We report a case of a woman with a type 1 gastric carcinoid in which, for the presence of an extended micro-polyposis of the fundus a total gastrectomy was necessary for treatment.

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17947953.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


67. Lerwill MF, Young RH: Ovarian metastases of intestinal-type gastric carcinoma: A clinicopathologic study of 4 cases with contrasting features to those of the Krukenberg tumor. Am J Surg Pathol; 2006 Nov;30(11):1382-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian metastases of intestinal-type gastric carcinoma: A clinicopathologic study of 4 cases with contrasting features to those of the Krukenberg tumor.
  • Ovarian metastases of intestinal-type gastric adenocarcinomas are rare, and information on them is very limited compared with that on signet-ring cell carcinomas that result in the Krukenberg tumor.
  • In the other 2 cases, the ovarian tumors had a mucinous appearance, 1 being dominantly cystic with occasional goblet cells and the other with prominent foveolar-type cells.
  • Although information is limited, our results suggest that metastatic spread to the ovary by intestinal-type gastric adenocarcinoma is usually seen in patients older than those with Krukenberg tumors, with a known history of gastric carcinoma, and with concomitant widespread disease.
  • Involvement of the ovary by intestinal-type gastric carcinoma produces a microscopic picture distinctly different from that of a Krukenberg tumor.
  • These metastatic intestinal-type tumors may be confused with metastases from other gastrointestinal sites that are more frequently the cause of pseudoendometrioid or mucinous metastases, and like such tumors may be confused with primary ovarian endometrioid and mucinous neoplasms.
  • [MeSH-major] Adenocarcinoma / secondary. Krukenberg Tumor / pathology. Ovarian Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Intestinal Neoplasms / metabolism. Intestinal Neoplasms / pathology. Middle Aged


68. Tsutsumi K, Ohtsuka T, Oda Y, Sadakari Y, Mori Y, Aishima S, Takahata S, Nakamura M, Mizumoto K, Tanaka M: A history of acute pancreatitis in intraductal papillary mucinous neoplasms of the pancreas is a potential predictive factor for malignant papillary subtype. Pancreatology; 2010;10(6):707-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pancreatitis group had a significantly higher frequency of carcinoma derived from IPMNs than the nonpancreatitis group (p = 0.03).
  • The incidence of intestinal-type IPMNs in the pancreatitis group was significantly higher than that in the nonpancreatitis group (p < 0.001).
  • CONCLUSION: Acute pancreatitis associated with IPMNs could predict malignant intestinal-type tumor. and IAP.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology. Pancreatitis / diagnosis

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 S. Karger AG, Basel.
  • (PMID = 21242711.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


69. Martins FP, Artigiani Neto R, Oshima CT, Costa PP, N M F, Ferrari AP: Over-expression of cyclooxygenase-2 in endoscopic biopsies of ectopic gastric mucosa. Braz J Med Biol Res; 2007 Nov;40(11):1447-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rare cases of adenocarcinoma have been described.
  • EGM biopsies were evaluated with respect to type of epithelium, presence of H. pylori, and inflammation.
  • Histological examination revealed fundic type epithelium in 58.3% of cases, H. pylori was present in 50% and chronic inflammation in 66.7%.
  • COX-2 immunoexpression in EGM was not related to gender, age, epithelium type, presence of inflammation or intestinal metaplasia, H. pylori infection, or any endoscopic finding.

  • MedlinePlus Health Information. consumer health - Esophagus Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17934641.001).
  • [ISSN] 1414-431X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


70. Leal M, Lima E, Silva P, Assumpção P, Calcagno D, Payão S, Burbano RR, Smith M: Promoter hypermethylation of CDH1, FHIT, MTAP and PLAGL1 in gastric adenocarcinoma in individuals from Northern Brazil. World J Gastroenterol; 2007 May 14;13(18):2568-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter hypermethylation of CDH1, FHIT, MTAP and PLAGL1 in gastric adenocarcinoma in individuals from Northern Brazil.
  • METHODS: Methylation-specific PCR (MSP) assay was performed in 13 nonneoplastic gastric adenocarcinoma, 30 intestinal-type gastric adenocarcinoma and 35 diffuse-type gastric adenocarcinoma samples from individuals in Northern Brazil.
  • Hypermethylation of three or four genes revealed a significant association with diffuse-type gastric cancer compared with nonneoplastic cancer.
  • A higher hypermethylation frequency was significantly associated with H pylori infection in gastric cancers, especially with diffuse-type.
  • MTAP hypermethylation was associated with H pylori in gastric cancer samples, as well as with diffuse-type compared with intestinal-type.
  • In diffuse-type, MTAP hypermethylation was associated with female gender.
  • MTAP promoter hypermethylation can be characterized as a marker of diffuse-type gastric cancer, especially in women and may help in diagnosis, prognosis and therapies.
  • This infection may be correlated with the carcinogenic process through the gene promoter hypermethylation, especially the MTAP promoter in diffuse-type.
  • A higher H pylori infection in diffuse-type may be due to greater genetic predisposition.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Methylation. Proteins / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):49868-73 [14506228.001]
  • [Cites] Am J Pathol. 2004 Feb;164(2):689-99 [14742272.001]
  • [Cites] Biochim Biophys Acta. 2004 Nov 5;1690(3):276-84 [15511635.001]
  • [Cites] Cancer Res. 1991 Mar 1;51(5):1448-51 [1997184.001]
  • [Cites] Biochim Biophys Acta. 1994 May 27;1198(1):11-26 [8199193.001]
  • [Cites] Cell. 1996 Feb 23;84(4):587-97 [8598045.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1595-604 [10587350.001]
  • [Cites] Nature. 2000 Mar 23;404(6776):398-402 [10746728.001]
  • [Cites] N Engl J Med. 2001 Jun 21;344(25):1904-9 [11419427.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2294-301 [11413518.001]
  • [Cites] Genes Dev. 2002 Jan 1;16(1):6-21 [11782440.001]
  • [Cites] Arq Gastroenterol. 2001 Oct-Dec;38(4):240-6 [12068534.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5427-40 [12154405.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):399-403 [12163364.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • [Cites] Cancer Biol Ther. 2002 May-Jun;1(3):232-6 [12432269.001]
  • [Cites] Mol Cell Biol. 2003 Feb;23(3):988-1003 [12529403.001]
  • [Cites] Gut. 2003 Apr;52(4):502-6 [12631658.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1193-201 [12730860.001]
  • [Cites] Yi Chuan Xue Bao. 2003 Feb;30(2):103-8 [12776596.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):683-90 [12875987.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):592-600 [12894247.001]
  • [Cites] Cancer Res. 1996 Dec 15;56(24):5653-8 [8971171.001]
  • [Cites] EMBO J. 1997 May 15;16(10):2814-25 [9184226.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3429-34 [9699676.001]
  • [Cites] J Biol Chem. 1998 Sep 4;273(36):23026-32 [9722527.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5032-7 [9823304.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Cancer Sci. 2004 Dec;95(12):962-8 [15596045.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Int J Oncol. 2005 Jun;26(6):1493-500 [15870861.001]
  • [Cites] World J Gastroenterol. 2005 Sep 7;11(33):5174-9 [16127748.001]
  • [Cites] Rev Med Chil. 2005 Aug;133(8):874-80 [16163424.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):748-60 [16207477.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):64-72 [16081515.001]
  • [Cites] Cancer Sci. 2006 Jan;97(1):64-71 [16367923.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):199-203 [16482618.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1250-9 [16475210.001]
  • [Cites] Diagn Mol Pathol. 2006 Mar;15(1):24-9 [16531765.001]
  • [Cites] Arch Dermatol. 2006 Apr;142(4):471-6 [16618867.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3216-21 [16707623.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(4):651-74 [16997151.001]
  • [Cites] J Cell Physiol. 2007 Jan;210(1):16-25 [17063461.001]
  • (PMID = 17552003.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CDH1 protein, human; 0 / Cadherins; 0 / Cell Cycle Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / PLAGL1 protein, human; 0 / Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  • [Other-IDs] NLM/ PMC4146816
  •  go-up   go-down


71. Mukai K, Ishida Y, Okajima K, Isozaki H, Morimoto T, Nishiyama S: Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer; 2006;9(3):192-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In EGCs, the detection rate of the intestinal type, according to Lauren's classification (43.8%) was significantly higher than that of the diffuse type (0%).
  • Two of the 7 EGC patients who were PET-positive had nodal involvement and their tumors were the intestinal type.
  • In EGCs, only the intestinal type was detectable by PET.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Stomach Neoplasms / diagnostic imaging

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Feb;231(2):229-34 [10674615.001]
  • [Cites] J Nucl Med. 2000 Sep;41(9):1561-8 [10994739.001]
  • [Cites] J Nucl Med. 1991 Nov;32(11):2118-23 [1834814.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3202-10 [10986052.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):634-41 [11505409.001]
  • [Cites] N Engl J Med. 2000 Jul 27;343 (4):254-61 [10911007.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Ann Nucl Med. 2003 Dec;17 (8):733-8 [14971621.001]
  • [Cites] World J Surg. 2004 Mar;28(3):247-53 [14961197.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2002 Apr;16(2):237-51 [11969236.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2383-90 [15856477.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):288-95 [12552348.001]
  • [Cites] Clin Positron Imaging. 1998 Sep;1(4):213-221 [14516555.001]
  • (PMID = 16952037.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


72. Kolodziejczyk P, Kulig J, Popiela T, Sierzega M, Jedrys J, Czupryna A, Kubisz A, Szczepanik A, Klek S, Polish Gastric Cancer Study Group: Outcome of gastric cancer surgery in elderly patients. Hepatogastroenterology; 2005 Nov-Dec;52(66):1911-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of the intestinal type according to Lauren (55.9% vs. 43.9%;p<0.05) and distally-located cancers (40.8% vs. 31.3%; p<0.05) was higher in group I.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Postoperative Complications / epidemiology. Stomach Neoplasms / mortality. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334805.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


73. Xin S, Huixin C, Benchang S, Aiping B, Jinhui W, Xiaoyan L, Yu WB, Minhu C: Expression of Cdx2 and claudin-2 in the multistage tissue of gastric carcinogenesis. Oncology; 2007;73(5-6):357-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Altogether, we analyzed 108 chronic superficial gastritis, 55 chronic atrophic gastritis, 109 intestinal-type metaplasia, 93 dysplasia and 52 gastric intestinal-type adenocarcinoma samples.
  • Our results indicated that the percentage of Cdx2-positive cases was 0% (0/108) for chronic superficial gastritis, 0% (0/55) for chronic atrophic gastritis, 90.83% (99/109) for intestinal-type metaplasia, 51.61% (48/93) for dysplasia and 61.54% (32/52) for gastric intestinal-type adenocarcinoma, primarily expressed in the cell nucleus and partly in the cytoplasm (p < 0.05); interestingly, the percentage for the intestine-type metaplasia was markedly high.
  • The percentage of claudin-2-positive cases was 0% (0/108) for chronic superficial gastritis, 0% (0/55) for chronic atrophic gastritis, 0% (0/109) for intestinal-type metaplasia, 35.48% (33/93) for dysplasia and 71.15% (37/52) for gastric intestinal-type adenocarcinoma, primarily in the cell membrane and gradually increased in the multistage process of gastric carcinogenesis (p < 0.05).
  • Significant correlations were found between claudin-2 and Cdx2 protein expression in dysplasia and intestine-type adenocarcinoma (r = 0.112, p < 0.05).
  • [MeSH-major] Adenocarcinoma / pathology. Homeodomain Proteins / metabolism. Intestinal Neoplasms / pathology. Membrane Proteins / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel.
  • (PMID = 18500171.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / CLDN2 protein, human; 0 / Claudins; 0 / Homeodomain Proteins; 0 / Membrane Proteins
  •  go-up   go-down


74. Iguchi H, Uyama T, Kanazawa A, Amatsu H, Yamane H, Kusuki M, Nakamura A: [A successful case of advanced nasal adenocarcinoma treated with tumor dormancy therapy with S -1 alone]. Gan To Kagaku Ryoho; 2008 Dec;35(13):2389-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A successful case of advanced nasal adenocarcinoma treated with tumor dormancy therapy with S -1 alone].
  • We report a 65-year-old female case of low-grade non-intestinal type adenocarcinoma of the nasal cavity with bilateral metastases to the cervical lymph nodes(T3N2cM0: Stage IV A).
  • Although the effectiveness of S-1 for adenocarcinoma of the head and neck has not been fully demonstrated, S-1 might be useful in patients with advanced head and neck adenocarcinoma for the purpose of TDT.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Nose Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19098408.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


75. Salas-Valverde S, Lizano A, Gamboa Y, Vega S, Barrantes M, Santamaría S, Zamora JB: Colon carcinoma in children and adolescents: prognostic factors and outcome-a review of 11 cases. Pediatr Surg Int; 2009 Dec;25(12):1073-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon carcinoma in children and adolescents: prognostic factors and outcome-a review of 11 cases.
  • BACKGROUND: Carcinoma of the colon and rectum is rare in the pediatric age group, and usually presents with an advanced stage disease bearing a poor prognosis.
  • Colorectal carcinoma should be considered in children with signs of intestinal obstruction, alteration in bowel habits, gastrointestinal bleeding and chronic abdominal pain.
  • METHODS: Between 1974 and 2007, 11 patients were identified and treated for colorectal carcinoma at the Oncology Unit.
  • Abdominal pain, acute intestinal obstruction, rectal bleeding and weight loss were the commonest symptoms.
  • Surgical procedures were done in 11 patients (incomplete resection with segmental resection in 4 patients, complete resection in the other 4, and biopsy alone in 3 patients).The predominant histological type was mucinous carcinoma.
  • CONCLUSIONS: Colorectal carcinoma in children is very uncommon and could be easily misdiagnosed, resulting in advanced stage disease at diagnosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Antineoplastic Agents / therapeutic use. Colectomy / methods. Colonic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2005 Jan;27(1):39-41 [15654277.001]
  • [Cites] Cancer. 1958 Jul-Aug;11(4):855-7 [13561255.001]
  • [Cites] Surg Gynecol Obstet. 1962 Apr;114:438-42 [13898554.001]
  • [Cites] J Pediatr Surg. 1976 Dec;11(6):967-71 [1003308.001]
  • [Cites] Clin Genet. 1987 Jan;31(1):35-44 [3568432.001]
  • [Cites] Am Surg. 1998 Sep;64(9):849-53 [9731812.001]
  • [Cites] Pediatrics. 1963 Oct;32:558-71 [14069097.001]
  • [Cites] J Chemother. 2002 Jun;14(3):301-8 [12120887.001]
  • [Cites] J Pediatr Surg. 1992 Aug;27(8):1085-9; discussion 1089-90 [1403541.001]
  • [Cites] Eur J Pediatr Surg. 2003 Feb;13(1):66-8 [12664421.001]
  • [Cites] Dis Colon Rectum. 1976 Sep;19(6):529-34 [183939.001]
  • [Cites] Eur J Pediatr Surg. 2001 Oct;11(5):338-41 [11719875.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):952-5 [4016687.001]
  • [Cites] Cancer. 1985 Mar 15;55(6):1322-6 [3971300.001]
  • [Cites] J Pediatr Surg. 1999 Oct;34(10):1499-504 [10549756.001]
  • [Cites] J Pediatr Surg. 1992 Jul;27(7):919-21 [1640344.001]
  • [Cites] J Pediatr Surg. 1993 Sep;28(9):1188-93 [8308690.001]
  • [Cites] Arch Surg. 1970 Apr;100(4):527-31 [4190476.001]
  • [Cites] Dis Colon Rectum. 1981 Jan-Feb;24(1):25-8 [7472098.001]
  • [Cites] Surgery. 1983 Mar;93(3):409-14 [6600855.001]
  • [Cites] Am J Surg. 1958 Jul;96(1):47-53 [13545485.001]
  • [Cites] Surg Gynecol Obstet. 1974 Feb;138(2):169-70 [4810853.001]
  • [Cites] Br J Surg. 1984 Apr;71(4):272-7 [6704677.001]
  • [Cites] Cancer. 1976 Apr;37(4):1891-1900 [177180.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1560-2 [14605580.001]
  • [Cites] Cancer. 1977 Nov;40(5 Suppl):2464-72 [200342.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):209-11 [17255833.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5808-14 [18089879.001]
  • [Cites] J Pediatr Surg. 1989 Nov;24(11):1189-91 [2553912.001]
  • [Cites] South Med J. 1976 Jan;69(1):24-7 [1246645.001]
  • (PMID = 19816697.001).
  • [ISSN] 1437-9813
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


76. Burbano RR, Assumpção PP, Leal MF, Calcagno DQ, Guimarães AC, Khayat AS, Takeno SS, Chen ES, De Arruda Cardoso Smith M: C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil. Anticancer Res; 2006 Jul-Aug;26(4B):2909-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil.
  • Chromosomal gains were the most frequent finding, losses occurring only in the diffuse type.
  • 1, where C-MYC is located, was the main finding, exclusively in the intestinal type with metastasis.
  • CONCLUSION: C-MYC locus amplification may be predictor of aggressiveness in intestinal-type gastric cancer, playing an important role in its development and progression.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Genes, myc. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886612.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


77. Botelho NK, Schneiders FI, Lord SJ, Freeman AK, Tyagi S, Nancarrow DJ, Hayward NK, Whiteman DC, Lord RV: Gene expression alterations in formalin-fixed, paraffin-embedded Barrett esophagus and esophageal adenocarcinoma tissues. Cancer Biol Ther; 2010 Jul 15;10(2):172-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression alterations in formalin-fixed, paraffin-embedded Barrett esophagus and esophageal adenocarcinoma tissues.
  • RESULTS: 30 genes were significantly differentially expressed by histopathology tissue type.
  • Strong associations between histopathology type and gene expression were observed with the overexpressed genes: cyclo-oxygenase-2 (COX-2), for which histopathology type explained 77.7% of the variation in expression, TSPAN1 (73.5%), TSPAN8 (62.9%), SPARC (62.1%), MMP7 (50.8%); and the under-expressed genes ADH7 (53.7%), APC (58.2%), RAR-gamma (51.3%).
  • METHODS: mRNA was isolated from 54 FFPE small endoscopic biopsies from patients with Barrett intestinal metaplasia (BE), esophageal adenocarcinoma (EAC), or control patients with a normal squamous-lined esophagus.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. Esophageal Neoplasms / genetics. Gene Expression Profiling / methods. Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20543560.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


78. Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z: Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology; 2009 Aug;137(2):588-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome.
  • BACKGROUND & AIMS: Gastroesophageal reflux causes inflammation and intestinal metaplasia and its downstream sequelum adenocarcinoma in the distal esophagus.
  • The incidence of esophageal adenocarcinoma has increased approximately 6-fold in the United States since the 1970s, accompanied with a significant increase in the prevalence of gastroesophageal reflux disease (GERD).
  • Host phenotypes were histologically defined as normal, esophagitis, or Barrett's esophagus (intestinal metaplasia).
  • The type I microbiome was dominated by the genus Streptococcus and concentrated in the phenotypically normal esophagus.
  • Conversely, the type II microbiome contained a greater proportion of gram-negative anaerobes/microaerophiles and primarily correlated with esophagitis (odds ratio, 15.4) and Barrett's esophagus (odds ratio, 16.5).
  • CONCLUSIONS: In the human distal esophagus, inflammation and intestinal metaplasia are associated with global alteration of the microbiome.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):732-7 [16407106.001]
  • [Cites] J Clin Microbiol. 2005 Nov;43(11):5721-32 [16272510.001]
  • [Cites] Cell. 2006 Feb 24;124(4):837-48 [16497592.001]
  • [Cites] BMC Bioinformatics. 2006;7:371 [16893466.001]
  • [Cites] World J Gastroenterol. 2006 Nov 14;12(42):6741-6 [17106919.001]
  • [Cites] Nature. 2006 Dec 21;444(7122):1022-3 [17183309.001]
  • [Cites] Nature. 2006 Dec 21;444(7122):1027-31 [17183312.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D169-72 [17090583.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Jan;5(1):17-26 [17142109.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2927-32 [17293459.001]
  • [Cites] Appl Environ Microbiol. 2007 Aug;73(16):5261-7 [17586664.001]
  • [Cites] Nucleic Acids Res. 2008 Oct;36(18):e120 [18723574.001]
  • [Cites] World J Gastroenterol. 2005 Dec 14;11(46):7277-83 [16437628.001]
  • [Cites] Science. 2000 Apr 14;288(5464):287-93 [10777411.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Jan;280(1):G32-42 [11123195.001]
  • [Cites] Am J Clin Nutr. 2001 Feb;73(2 Suppl):386S-392S [11157346.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2395-8 [11289103.001]
  • [Cites] Science. 2001 May 11;292(5519):1115-8 [11352068.001]
  • [Cites] J Bacteriol. 2001 Jun;183(12):3770-83 [11371542.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Aug;15(8):1219-25 [11472326.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Appl Environ Microbiol. 2002 Aug;68(8):3673-82 [12147459.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4250-5 [15016918.001]
  • [Cites] J Theor Biol. 2004 Jun 21;228(4):523-37 [15178200.001]
  • [Cites] Gastroenterology. 1985 Oct;89(4):797-804 [4029559.001]
  • [Cites] Int J Syst Bacteriol. 1998 Jul;48 Pt 3:921-7 [9734047.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1434-42 [10364004.001]
  • [Cites] Rep US Army Med Res Lab. 1963 Jun 7;:1-9 [14133525.001]
  • [Cites] Chest. 2004 Nov;126(5):1490-4 [15539717.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11070-5 [16033867.001]
  • [Cites] Trends Microbiol. 2005 Oct;13(10):469-75 [16112578.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2299-306 [16181384.001]
  • [Cites] N Engl J Med. 2005 Nov 3;353(18):1899-911 [16267321.001]
  • [CommentIn] Gastroenterology. 2009 Aug;137(2):419-21 [19563840.001]
  • (PMID = 19394334.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI063477-05; United States / NCI NIH HHS / CA / R01 CA097946; United States / NCI NIH HHS / CA / UH2CA140233; United States / NCI NIH HHS / CA / CA140233-01; United States / NCI NIH HHS / CA / R01 CA097946-04; United States / NCI NIH HHS / CA / R01CA97946; United States / NIAID NIH HHS / AI / R01AI063477; United States / NIAID NIH HHS / AI / AI063477-05; United States / NCI NIH HHS / CA / UH2 CA140233-01; United States / NCI NIH HHS / CA / UH2 CA140233; United States / NCI NIH HHS / CA / CA097946-04; United States / NIAID NIH HHS / AI / R01 AI063477
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS135974; NLM/ PMC2963147
  •  go-up   go-down


79. Rodríguez Santiago JM, Clemares M, Roig-Garcia J, Asensio JI, Feliu X, Toscano E, Resa J, Targarona E, Ibáñez-Aguirre J, Castell J, Sanfeliu G, Sánchez Cano JJ, Ramón JM, Del Olmo MF, Gutiérrez A, Arteaga J, Vázquez J, Mozos FL, Vallejo FM, Registro Nacional Cirugía Gástrica por Laparoscopia: [Gastric cancer and laparoscopy: analysis of data from the national register of laparoscopic gastric surgery]. Cir Esp; 2009 May;85(5):280-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the data from the Laparoscopic Gastric Surgery Spanish National Register of laparoscopic Gastric Surgery and to analyse the type of surgery, the conversion to laparotomy, postoperative complications and mortality.
  • RESULTS: A total of 245 patients had gastric adenocarcinoma, 35 of them stromal tumours and 22 other gastric pathologies.
  • In gastric adenocarcinoma patients, resection was performed in 232 cases (95%).
  • The most frequent histology was intestinal, mainly located in the distal third of the stomach, with 34% of the tumours being locally advanced.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19371864.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


80. Theuer CP, Al-Kuran R, Akiyama Y, Okumura M, Ziogas A, Carpenter PM: Increased epithelial cadherin expression among Japanese intestinal-type gastric cancers compared with specimens from American patients of European descent. Am Surg; 2006 Apr;72(4):332-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased epithelial cadherin expression among Japanese intestinal-type gastric cancers compared with specimens from American patients of European descent.
  • E-cadherin expression, however, was significantly higher among intestinal cancers from the two countries: 56.3 per cent of cells from intestinal or mixed cancers from Japan (n = 32) expressed E-cadherin compared with 22.2 per cent of American specimens (n = 12; P = 0.008).
  • E-cadherin expression, a favorable prognostic factor, is more common in Japanese intestinal-type gastric cancer not involving the gastroesophageal junction.
  • [MeSH-major] Adenocarcinoma / metabolism. Asian Continental Ancestry Group. Cadherins / metabolism. European Continental Ancestry Group. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16676859.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / KO7CA74974
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


81. Resto VA, Krane JF, Faquin WC, Lin DT: Immunohistochemical distinction of intestinal-type sinonasal adenocarcinoma from metastatic adenocarcinoma of intestinal origin. Ann Otol Rhinol Laryngol; 2006 Jan;115(1):59-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical distinction of intestinal-type sinonasal adenocarcinoma from metastatic adenocarcinoma of intestinal origin.
  • OBJECTIVES: Distinction of intestinal-type sinonasal adenocarcinoma (ITAC) from adenocarcinoma of intestinal origin metastatic to the sinonasal cavity may be extremely difficult on histologic grounds alone.
  • We studied the role of cytokeratin (CK) and mucin (MUC) expression in differentiating ITAC, metastatic adenocarcinoma of intestinal origin, and non-intestinal-type sinonasal adenocarcinoma (non-ITAC).
  • METHODS: We stained specimens from 5 cases of ITAC and 4 cases of non-ITAC, along with 4 colonic and 3 duodenal adenocarcinoma controls, with CK7 and CK20, MUC2 and MUC5, neuron-specific enolase (NSE), chromogranin (CHR), and carcinoembryonic antigen (CEA) in order to examine the possible combinations of markers that best aid in the diagnosis of these lesions.
  • RESULTS: CK7 staining was positive in all ITAC and non-ITAC cases, whereas all cases displaying gastrointestinal-type differentiation (ITAC and metastatic intestinal cases) stained positive for both CK20 and MUC2.
  • [MeSH-major] Adenocarcinoma / metabolism. Colonic Neoplasms / metabolism. Duodenal Neoplasms / metabolism. Keratins / metabolism. Mucins / metabolism. Paranasal Sinus Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16466101.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins; 68238-35-7 / Keratins
  •  go-up   go-down


82. Westgaard A, Schjølberg AR, Cvancarova M, Eide TJ, Clausen OP, Gladhaug IP: Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours. Histopathology; 2009 Feb;54(3):337-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To examine how accurately immunohistochemical markers discriminate between pancreatobiliary and intestinal-type adenocarcinomas in the pancreatic head and to explore the prognostic importance of these markers among each of these histological types.
  • METHODS AND RESULTS: Histopathological features of 114 consecutively resected adenocarcinomas of pancreatobiliary (n = 67) and intestinal (n = 47) type of differentiation were recorded according to a standardized protocol.
  • Classification of the adenocarcinomas based on immunohistochemistry was compared with the morphological evaluation of histological type.
  • Presence of CK7 and MUC4, and absence of CDX2, were independent predictors of pancreatobiliary versus intestinal type.
  • [MeSH-major] Adenocarcinoma / pathology. Antigens, Differentiation / metabolism. Bile Duct Neoplasms / pathology. Mucin-1 / metabolism. Mucin-4 / metabolism. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Gene Expression. Humans. Immunohistochemistry. Intestinal Neoplasms / pathology. Prognosis. Survival Analysis


83. Kunze E, Krassenkova I, Fayyazi A: Tumor-associated neoexpression of the pS2 peptide and MUC5AC mucin in primary adenocarcinomas and signet ring cell carcinomas of the urinary bladder. Histol Histopathol; 2008 05;23(5):539-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenocarcinomas which secrete the pS2 peptide and the MUC5AC glycoprotein are proposed to be subclassified as adenocarcinomas of the intestinal type, as distinguished from those of the common type lacking an expression.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Signet Ring Cell / metabolism. Mucins / metabolism. Tumor Suppressor Proteins / metabolism. Urinary Bladder Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18283638.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucins; 0 / Neoplasm Proteins; 0 / TFF1 protein, human; 0 / Trefoil Factor-1; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


84. Tamura H, Ohtsuka M, Washiro M, Kimura F, Shimizu H, Yoshidome H, Kato A, Seki N, Miyazaki M: Reg IV expression and clinicopathologic features of gallbladder carcinoma. Hum Pathol; 2009 Dec;40(12):1686-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reg IV expression and clinicopathologic features of gallbladder carcinoma.
  • Regenerating islet-derived family, member 4 (Reg IV) has been shown to be associated with colorectal carcinogenesis and gastric carcinogenesis through intestinal metaplasia.
  • In this study, we examined Reg IV expression in the gallbladder and gallbladder carcinoma, and measured Reg IV levels in sera from patients with gallbladder carcinoma.
  • Immunohistochemically, although only a small part of the epithelium with intestinal metaplasia in 2 of 4 cases with adenomyomatosis showed Reg IV expression, Reg IV was negative in all cases with normal gallbladder (n = 15) and cholelithiasis (n = 13).
  • Expression was more frequently observed in well to moderately differentiated than in poorly differentiated adenocarcinomas and significantly correlated with expression of caudal-related homeobox transcription factor (a candidate for involvement in the induction of intestinal metaplasia).
  • Multivariate analysis revealed negative Reg IV expression, as well as hepatic parenchymal invasion, to be independently associated with a poor prognosis in patients with advanced gallbladder carcinoma.
  • Before surgical resection, 4 (33%) of 12 patients with gallbladder carcinoma had high serum Reg IV levels, whereas Reg IV was never elevated in 12 patients with benign diseases.
  • These results suggest that Reg IV is involved in gallbladder carcinoma carcinogenesis through intestinal metaplasia and is associated with relatively favorable prognosis in patients after surgery.
  • [MeSH-major] Adenocarcinoma / metabolism. Gallbladder Neoplasms / metabolism. Lectins, C-Type / biosynthesis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19716164.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Lectins, C-Type; 0 / REG4 protein, human
  •  go-up   go-down


85. Evangelou K, Kotsinas A, Mariolis-Sapsakos T, Giannopoulos A, Tsantoulis PK, Constantinides C, Troupis TG, Salmas M, Kyroudis A, Kittas C, Gorgoulis VG: E2F-1 overexpression correlates with decreased proliferation and better prognosis in adenocarcinomas of Barrett oesophagus. J Clin Pathol; 2008 May;61(5):601-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: As oesophageal adenocarcinomas occur almost exclusively in the metaplastic Barrett epithelium and the opposing E2F-1 behaviour seems to be cell and tissue-type dependent, we examined the manner in which E2F-1 acts in ACs of Barrett oesophagus.
  • These findings are opposite from those seen in OSCCs, suggesting that the tumour-suppressing E2F-1 behaviour in oesophageal adenocarcinomas is possibly due to the intestinal-type nature of the metaplastic Barrett mucosa.
  • [MeSH-major] Adenocarcinoma / metabolism. Barrett Esophagus / metabolism. Biomarkers, Tumor / metabolism. E2F1 Transcription Factor / metabolism. Esophageal Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17908803.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / E2F1 Transcription Factor; 0 / E2F1 protein, human; 0 / Neoplasm Proteins
  •  go-up   go-down


86. Petrou A, Papalambros A, Katsoulas N, Bramis K, Evangelou K, Felekouras E: Primary appendiceal mucinous adenocarcinoma alongside with situs inversus totalis: a unique clinical case. World J Surg Oncol; 2010;8:49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary appendiceal mucinous adenocarcinoma alongside with situs inversus totalis: a unique clinical case.
  • INTRODUCTION: Mucinous adenocarcinoma is a rare neoplasm of the gastrointestinal tract and one of the three major histological subtypes of the primary appendiceal adenocarcinoma.
  • The most common type of presentation is that of acute appendicitis and the diagnosis is usually occurred after appendectomy.
  • The accurate preoperative diagnosis and management of the above condition represents a real challenge when uncommon anatomic anomalies such intestinal malrotation and situs inversus take place.
  • Pathologic evaluation established primary mucinous adenocarcinoma of the appendix and three months afterwards the patient underwent a subsequent extended left hemicolectomy.
  • CONCLUSION: In conclusion, the occurrence of primary appendiceal mucinous adenocarcinoma along with situs inversus, definitely accounts as a unique clinical case.
  • Even synchronous manifestation of primary mucinous adenocarcinoma of the appendix and situs inversus totalis represents an unusual anatomo-pathological entity, all physicians should be familiar having the knowledge to make an appropriate and accurate diagnosis that will lead to prompt and correct treatment.
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Appendiceal Neoplasms / complications. Situs Inversus / complications

  • Genetic Alliance. consumer health - Situs inversus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2001 Dec;8(10):787-95 [11776492.001]
  • [Cites] Oncol Rep. 2008 Sep;20(3):517-23 [18695900.001]
  • [Cites] Minerva Chir. 2002 Oct;57(5):695-8 [12370673.001]
  • [Cites] Br J Surg. 2004 Mar;91(3):304-11 [14991630.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):474-80 [14978617.001]
  • [Cites] Am Surg. 2004 Jul;70(7):593-9 [15279181.001]
  • [Cites] Ann Surg. 1976 Jan;183(1):53-7 [1247301.001]
  • [Cites] Am J Surg. 1994 Dec;168(6):685-7 [7978019.001]
  • [Cites] Br J Surg. 1995 Mar;82(3):299-306 [7795991.001]
  • [Cites] Dis Colon Rectum. 1995 Aug;38(8):848-52 [7634979.001]
  • [Cites] Am J Proctol. 1963 Dec;14:265-81 [14098730.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):69-76 [16389186.001]
  • [Cites] Ann Surg Oncol. 2006 May;13(5):624-34 [16538401.001]
  • [Cites] Br J Surg. 2006 Jul;93(7):783-92 [16775823.001]
  • [Cites] Am J Cardiol. 2007 Jul 15;100(2):305-9 [17631088.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):125-33 [18030535.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):526-34 [18043976.001]
  • [Cites] Am J Health Syst Pharm. 2008 Jun 1;65(11 Suppl 4):S3-7; quiz S22-4 [18499888.001]
  • [Cites] Ann Surg Oncol. 2008 Aug;15(8):2137-45 [18493824.001]
  • [Cites] Jpn J Clin Oncol. 2008 Jul;38(7):493-6 [18567598.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3307-12 [12115365.001]
  • (PMID = 20525349.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2894825
  •  go-up   go-down


87. Almeida R, Almeida J, Shoshkes M, Mendes N, Mesquita P, Silva E, Van Seuningen I, Reis CA, Santos-Silva F, David L: OCT-1 is over-expressed in intestinal metaplasia and intestinal gastric carcinomas and binds to, but does not transactivate, CDX2 in gastric cells. J Pathol; 2005 Dec;207(4):396-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] OCT-1 is over-expressed in intestinal metaplasia and intestinal gastric carcinomas and binds to, but does not transactivate, CDX2 in gastric cells.
  • Intestinal metaplasia (IM) is a preneoplastic lesion of the stomach in which there is transdifferentiation of the gastric mucosa to an intestinal phenotype.
  • The caudal-related homeobox gene CDX2 encodes an intestine-specific transcription factor crucial for the regulation of proliferation and differentiation of intestinal cells.
  • Furthermore, we evaluated OCT-1 binding by electrophoretic mobility shift assay and activation of the CDX2 promoter by co-transfecting a CDX2 promoter/reporter construct with an OCT-1 expression vector in two gastric carcinoma cell lines, GP220 and MKN45.
  • Furthermore, 74% of the gastric carcinomas were positive for OCT-1 and a strong association was observed between OCT-1 expression and intestinal-type carcinoma.
  • We identified that OCT-1 binds to the CDX2 promoter, although we could not see a transactivation effect in gastric carcinoma cell lines.
  • In conclusion, we observed increased OCT-1 expression in IM and in intestinal gastric carcinomas and identified the capacity of OCT-1 to bind to the CDX2 promoter, although we could not demonstrate a direct effect of OCT-1 in the transactivation of CDX2.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Pathological Society of Great Britain and Ireland.
  • (PMID = 16278805.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Neoplasm Proteins; 0 / Octamer Transcription Factor-1; 0 / Trans-Activators; 156560-97-3 / Cdx-2-3 protein
  •  go-up   go-down


88. Shin JA, An M, Choi JI, Kim SH, Lee WJ, Park SJ, Park JW, Hong EK: [A case of hepatectomy for liver metastasis after pancreatoduodenectomy for carcinoma of ampulla of Vater]. Korean J Gastroenterol; 2006 Dec;48(6):434-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of hepatectomy for liver metastasis after pancreatoduodenectomy for carcinoma of ampulla of Vater].
  • After curative resection of carcinoma of ampulla of Vater, 5-year survival rate has been reported ranging from 40% to 60%.
  • There have been few reports on long-term survivors after hepatectomy for metastatic liver tumors from carcinoma of ampulla of Vater.
  • We report a 42 year-old female patient with solitary hepatic metastasis from carcinoma of ampulla of Vater, which was successfully treated by hepatectomy 69 months after curative Whipple's operation.
  • Histologic examination of the resected specimen had revealed stage IB moderately-differentiated, intestinal type adenocarcinoma (T2N0M0).
  • Histologic study confirmed the presence of metastatic liver tumor from carcinoma of ampulla of Vater.
  • [MeSH-major] Ampulla of Vater. Carcinoma / diagnosis. Carcinoma / surgery. Common Bile Duct Neoplasms / pathology. Hepatectomy. Liver Neoplasms / diagnosis. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17189929.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


89. Chlumská A, Boudová L, Zámecník M: Sessile serrated adenomas of the large bowel. Clinicopathologic and immunohistochemical study including comparison with common hyperplastic polyps and adenomas. Cesk Patol; 2006 Jul;42(3):133-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sessile serrated adenoma (SSA) is a newly characterized type of the large bowel adenoma.
  • It arises in hyperplastic polyp (HP) and represents a precursor lesion of colorectal carcinoma with microsatellite instability.
  • The sites of SSAs were as follows: 8 in rectum, 4 in rectosigmoid colon, 1 in transverse colon, 1 next to mucinous carcinoma of ascending colon, 1 in anastomosis after resection of the transverse colon adenocarcinoma.
  • High-grade dysplasia was found only in SSA adjacent to mucinous adenocarcinoma.
  • Both MUC2 and MUC5A were also positive in mucinous carcinoma.
  • In previous studies these expressions were considered specific for serrated type of carcinogenesis.
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology. Intestinal Polyps / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma / pathology. Colonic Polyps / chemistry. Colonic Polyps / pathology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mucin 5AC. Mucin-2. Mucins / analysis. Neoplasms, Multiple Primary / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16955561.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


90. Bîrla R, Iosif C, Gîndea C, Hoară P, Constantinoiu S: [Clinical diagnosis of adenocarcinoma of the esophago-gastric junction]. Chirurgia (Bucur); 2007 Sep-Oct;102(5):511-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical diagnosis of adenocarcinoma of the esophago-gastric junction].
  • The aim of the work paper is to present the diagnosis methods of the esophago-gastric junction adenocarcinoma, based on our experience and literature data.
  • Early esophago-gastric junction (EGJ) adenocarcinoma (AC) is asymptomatic and its detection may be possible only through endoscopical surveillance.
  • For this reason is necessary to use some more precise methods for identifying intestinal metaplasia on distal esophagus, in patients with gastro-esophageal reflux disease, as well as for risk stratification in patients with dysplasia and for detection of intraepithelial neoplasia.
  • Applying modern methods of immunohistochemical and molecular diagnosis on endoscopical biopsy or esophageal brushing samples, the diagnosis rate for BE, dysplasia and early AC is improved and using the imaging means permits to obtain preoperative TNM staging and tumoral type (Siewert), with implications in therapeutical management.
  • [MeSH-major] Adenocarcinoma / diagnosis. Esophageal Neoplasms / diagnosis. Esophagogastric Junction. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018349.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 47
  •  go-up   go-down


91. Gao SG, Wang LD, Fan ZM, Li JL, He X, Guo RF, Xie DL, He XW, Gao SS, Guo HQ, Wang JK, Feng XS, Ma BG: Histochemical studies on intestinal metaplasia adjacent to gastric cardia adenocarcinoma in subjects at high-incidence area in Henan, north China. World J Gastroenterol; 2005 Aug 14;11(30):4634-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histochemical studies on intestinal metaplasia adjacent to gastric cardia adenocarcinoma in subjects at high-incidence area in Henan, north China.
  • AIM: To characterize the histochemical type and pattern of intestinal metaplasia (IM) adjacent to gastric cardia adenocarcinoma (GCA) and distal gastric cancer (GC) in Linzhou, Henan Province, China.
  • All the patients were from Linzhou, Henan Province, China, the highest incidence area for both GCA and squamous cell carcinoma.
  • The rates of both incomplete small intestinal and colonic IM types identified by histochemistry in GCA tissues (31.82% and 63.64%, respectively) were significantly higher than those in GC (5.33% and 21.33%, respectively, P<0.01).

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094701.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA065871; United States / NCI NIH HHS / CA / CA65871
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC4615402
  •  go-up   go-down


92. Kanechorn Na Ayuthaya R, Patthamapasphong N, Sura T, Niumpradit N, Trachoo O: Ehlers-Danlos syndrome type IV with gastric adenocarcinoma. J Med Assoc Thai; 2008;91 Suppl 1:S166-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ehlers-Danlos syndrome type IV with gastric adenocarcinoma.
  • The vascular type (type IV) is characterized by thin, translucent skin, easy bruising, characteristic facial appearance, and arterial, intestinal, and/or uterine fragility.
  • A first case of EDS type IV with adeno-carcinoma of the stomach in Thailand was reported and literature was reviewed.
  • Gastric biopsy was indicative of adenocarcinoma of the stomach and gastrectomy was done.
  • A vascular EDS type IV was diagnosed.
  • [MeSH-major] Adenocarcinoma / complications. Ehlers-Danlos Syndrome / etiology. Stomach Neoplasms / complications
  • [MeSH-minor] Collagen Type III / genetics. Fatal Outcome. Gastrectomy. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Ehlers-Danlos syndrome.
  • MedlinePlus Health Information. consumer health - Ehlers-Danlos Syndrome.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672610.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / COL3A1 protein, human; 0 / Collagen Type III
  •  go-up   go-down


93. Volkan Adsay N: Cystic lesions of the pancreas. Mod Pathol; 2007 Feb;20 Suppl 1:S71-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • New entities, in particular, intraductal papillary mucinous neoplasm and its variants, such as oncocytic and intestinal subtypes were recognized.
  • Consensus criteria for the distinction of these from the ordinary precursors of adenocarcinoma, the pancreatic intraepithelial neoplasia, were established.
  • The validity and clinical value of classifying the pancreatic cysts of mucinous type as adenoma, borderline, CIS and invasive have been established.
  • [MeSH-minor] Adenoma / pathology. Carcinoma in Situ / pathology. Humans. Pancreatic Ducts / pathology. Precancerous Conditions

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17486054.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Imano M, Satou T, Itoh T, Sakai K, Ishimaru E, Yasuda A, Peng YF, Shinkai M, Akai F, Yasuda T, Imamoto H, Okuno K, Ito H, Shiozaki H, Ohyanagi H: Immunohistochemical expression of osteopontin in gastric cancer. J Gastrointest Surg; 2009 Sep;13(9):1577-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathologically, intestinal type carcinoma showed strong expression of OPN.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5130-7 [11701665.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):610-23 [8080043.001]
  • [Cites] J Cell Biochem. 2002;85(4):728-36 [11968013.001]
  • [Cites] J Biol Chem. 1999 Jan 15;274(3):1729-35 [9880554.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Dec;17(6):463-74 [17113338.001]
  • [Cites] Exp Biol Med (Maywood). 2008 Dec;233(12 ):1537-45 [18849546.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):219-26 [9892210.001]
  • [Cites] Gastroenterology. 2008 Sep;135(3):956-68 [18555021.001]
  • [Cites] J Histochem Cytochem. 1994 Mar;42(3):351-61 [8308252.001]
  • [Cites] Invasion Metastasis. 1997;17(1):1-15 [9425320.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Sep;21(3):371-5 [12385580.001]
  • [Cites] J Cell Biochem. 1994 Sep;56(1):48-51 [7528752.001]
  • [Cites] Crit Rev Oncog. 1993;4(2):95-114 [8420573.001]
  • [Cites] Gynecol Oncol. 1997 Sep;66(3):439-48 [9299259.001]
  • [Cites] Expert Opin Ther Targets. 2007 Jan;11(1):81-90 [17150036.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):221-4 [9000558.001]
  • [Cites] J Clin Pathol. 1998 Jul;51(7):506-11 [9797726.001]
  • [Cites] Ann Surg Oncol. 2007 Dec;14(12):3419-27 [17896150.001]
  • [Cites] J Biol Chem. 1994 Jan 7;269(1):711-5 [7506262.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(8):2734-42 [10733576.001]
  • [Cites] J Cell Biol. 1998 May 18;141(4):1083-93 [9585425.001]
  • [Cites] Oncology. 2007;72(1-2):89-96 [18004082.001]
  • [Cites] J Surg Res. 2004 Oct;121(2):228-41 [15501463.001]
  • [Cites] Biochim Biophys Acta. 2001 Dec 28;1552(2):61-85 [11825687.001]
  • [Cites] Histopathology. 1996 Aug;29(2):123-9 [8872145.001]
  • [Cites] Oncogene. 1993 May;8(5):1211-9 [8479744.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2329-35 [10357401.001]
  • (PMID = 19582521.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin
  •  go-up   go-down


95. Tabrizi AD, Kalloger SE, Köbel M, Cipollone J, Roskelley CD, Mehl E, Gilks CB: Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. Int J Gynecol Pathol; 2010 Mar;29(2):99-107
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases.
  • Primary ovarian mucinous carcinomas of the intestinal type are uncommon and earlier reports have included cases diagnosed according to older, less stringent, criteria (which would now be considered borderline tumors) and variable numbers of cases of metastatic adenocarcinoma.
  • This study was conducted to identify all cases of primary mucinous carcinoma of the ovary in a population-based registry, diagnosed according to WHO 2003 criteria, and to characterize their histologic features, immunohistochemical expression profile, and outcome.
  • Thirty-one cases of primary ovarian mucinous carcinoma were included in this study.
  • Twenty-six of 31 (83.9%) tumors had expansile stromal invasion, 4 of 31 (12.9%) showed destructive invasion, and 1 of 31 (3.2%) had anaplastic carcinoma in a mural nodule.
  • At follow-up, 6 of 26 patients (23.1%) with tumors showing expansile invasion experienced a recurrence, compared with 1 of 4 patients (25%) with destructive invasion and the single patient (100%) with anaplastic carcinoma.
  • Our findings support current diagnostic criteria for primary ovarian mucinous carcinoma, that is, the presence of expansile invasion, in the absence of destructive invasion, warrants a diagnosis of carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173494.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


96. Takahashi H, Murai Y, Tsuneyama K, Nomoto K, Okada E, Fujita H, Takano Y: Overexpression of phosphorylated histone H3 is an indicator of poor prognosis in gastric adenocarcinoma patients. Appl Immunohistochem Mol Morphol; 2006 Sep;14(3):296-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of phosphorylated histone H3 is an indicator of poor prognosis in gastric adenocarcinoma patients.
  • However, correlations between phosphorylated histone H3 overexpression and clinicopathologic variables were noted for histologic type (intestinal type predominant in high labeling indices [LIs], defined as over the value of the 75th percentile; P<0.01), vessel invasion (positive in high LIs; P=0.05), and lymph node metastasis (positive in high LIs; P=0.04).
  • With regard to Ki-67 overexpression, no correlation was evident with the clinicopathologic variables except histologic type (intestinal type predominant; P=0.05).

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16932020.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Histones; 0 / Ki-67 Antigen
  •  go-up   go-down


97. Quinlan JM, Colleypriest BJ, Farrant M, Tosh D: Epithelial metaplasia and the development of cancer. Biochim Biophys Acta; 2007 Sep;1776(1):10-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metaplasia means the conversion, in postnatal life, of one cell type to another.
  • One of the best-described examples of metaplasia is Barrett's metaplasia or the appearance of intestinal-like columnar tissue in the oesophagus.
  • Barrett's metaplasia develops as a result of gastro-oesophageal reflux and is considered the precursor lesion for oesophageal adenocarcinoma.
  • While we know quite a bit about the molecular events associated with the development of oesophageal adenocarcinoma, our understanding of the initial events leading to Barrett's metaplasia is lacking.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17618050.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300415; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 137
  •  go-up   go-down


98. Hur K, Kwak MK, Lee HJ, Park DJ, Lee HK, Lee HS, Kim WH, Michaeli D, Yang HK: Expression of gastrin and its receptor in human gastric cancer tissues. J Cancer Res Clin Oncol; 2006 Feb;132(2):85-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was performed to investigate the prognostic significance and the expression profiles of gastrin and gastrin receptor in human gastric carcinoma tissues.
  • METHODS: We analyzed the expressions of gastrin and gastrin receptor by immunohistochemical staining using anti-gastrin Ab (Sigma, St. Louis, MO, USA) and anti-gastrin receptor Ab (Aphton Corp., Woodland, CA, USA) in 279 gastric adenocarcinoma patients.
  • Gastrin expression was significantly higher in men than in women (54.3% vs. 34.1%), and higher in differentiated gastric adenocarcinoma than in the undifferentiated type (55.1% vs. 43.0%).
  • The gastrin receptor expression rate was also significantly higher in men than in women (61.2% vs. 47.3%), and was higher in the differentiated type than in the undifferentiated type (72.9% vs. 46.5%), and significantly higher in the intestinal type than in the diffuse type (75.2% vs. 42.9%).
  • When focused on correlation between the co-expression of gastrin and gastrin/CCKB receptor and the survival, the prognosis of patients positive for both gastrin and gastrin receptor was significantly poorer than for those negative for gastrin and gastrin receptor in diffuse-type gastric cancer patients.
  • However, multivariate analysis showed that only TNM stage was an independent prognostic factor of survival in diffuse-type gastric cancer patients.
  • CONCLUSIONS: This study shows that the expression rates of gastrin and gastrin receptor are high (about a half) in gastric carcinoma tissues, and that there is an association between gastrin and gastrin receptor expression.
  • We also found that patients with diffuse-type gastric carcinoma tissues expressing both gastrin and gastrin receptor have a poorer prognosis than those negative for both, which suggests that gastrin acts as an autocrine growth factor in a subgroup of gastric carcinomas.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Gastrins / analysis. Receptor, Cholecystokinin B / analysis. Stomach Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1998 Aug;115(2):275-80 [9679032.001]
  • [Cites] Gastroenterology. 1986 Feb;90(2):391-9 [3510144.001]
  • [Cites] Annu Rev Physiol. 2001;63:49-76 [11181948.001]
  • [Cites] Eur J Biochem. 1993 Aug 1;215(3):513-29 [8354258.001]
  • [Cites] Mol Cell Biol. 2000 Jan;20(2):697-701 [10611248.001]
  • [Cites] Cancer Res. 1988 Feb 15;48(4):932-7 [3338085.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 6;94(5):375-83 [11880476.001]
  • [Cites] Gut. 1998 Jun;42(6):795-8 [9691917.001]
  • [Cites] Gastroenterology. 1992 Mar;102(3):767-78 [1537514.001]
  • [Cites] Gastroenterology. 1997 Sep;113(3):1015-25 [9287997.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):285-91 [11896207.001]
  • [Cites] Gastroenterology. 1993 May;104(5):1356-70 [8482449.001]
  • [Cites] Gastroenterology. 2000 Jan;118(1):36-47 [10611152.001]
  • [Cites] Lung Cancer. 2002 Jun;36(3):235-42 [12009231.001]
  • [Cites] Br J Cancer. 1989 Apr;59(4):554-8 [2713241.001]
  • [Cites] Am J Physiol. 1999 Oct;277(4 Pt 1):G773-84 [10516143.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):280-6 [8978369.001]
  • [Cites] Am J Physiol. 1994 Jan;266(1 Pt 2):R277-83 [8304551.001]
  • [Cites] Am J Physiol. 1993 Feb;264(2 Pt 1):G179-86 [8447399.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8691-5 [1528881.001]
  • [Cites] Pancreas. 2002 Mar;24(2):121-9 [11854616.001]
  • [Cites] Gastroenterology. 1990 Jan;98(1):33-8 [2293597.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Feb;282(2):G359-66 [11804858.001]
  • [Cites] Biopolymers. 2002;66(6):399-418 [12658727.001]
  • [Cites] Gut. 1999 Dec;45(6):812-7 [10562577.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S8-19 [7762739.001]
  • [Cites] Dig Dis Sci. 2001 Jul;46(7):1356-66 [11478485.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(3):276-85 [10982627.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3605-9 [1373504.001]
  • [Cites] Physiol Rev. 1988 Apr;68(2):456-502 [3282244.001]
  • [Cites] Eur J Pharmacol. 2003 Aug 1;474(1):21-9 [12909192.001]
  • [Cites] Br J Surg. 2001 Apr;88(4):564-8 [11298626.001]
  • [Cites] Gastroenterology. 1976 Feb;70(2):278-88 [765181.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11825-30 [8876222.001]
  • [Cites] J Lab Clin Med. 2003 May;141(5):335-41 [12761477.001]
  • (PMID = 16228228.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Gastrins; 0 / Receptor, Cholecystokinin B
  •  go-up   go-down


99. Hong SJ, Kwon KW, Kim SG, Ko BM, Ryu CB, Kim YS, Moon JH, Cho JY, Lee JS, Lee MS, Shim CS, Kim BS: Variation in expression of gastric leptin according to differentiation and growth pattern in gastric adenocarcinoma. Cytokine; 2006 Jan 21;33(2):66-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variation in expression of gastric leptin according to differentiation and growth pattern in gastric adenocarcinoma.
  • We compared the expression patterns of leptin and of the long variant of the leptin receptor (Ob-Rb) between areas with non-ulcerated mucosa and with hyperplastic polyps, adenoma, or adenocarcinoma to evaluate the expression relative to different disease states.
  • Leptin and Ob-Rb were expressed in hyperplastic polyps, adenoma, and adenocarcinoma.
  • In the gastric adenocarcinoma, leptin was expressed significantly less in the poorly differentiated and diffuse-type groups than in the well-differentiated and moderately differentiated groups or in the intestinal type.
  • Based upon our findings, we suggest the possibility that leptin expression can have a pathophysiologic role about the differentiation or growth pattern of gastric adenocarcinoma.
  • A further series of experiments is necessary to elucidate the pathophysiological role of leptin in the differentiation of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Leptin / metabolism. Stomach / metabolism. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434209.001).
  • [ISSN] 1043-4666
  • [Journal-full-title] Cytokine
  • [ISO-abbreviation] Cytokine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


100. Crusius JB, Canzian F, Capellá G, Peña AS, Pera G, Sala N, Agudo A, Rico F, Del Giudice G, Palli D, Plebani M, Boeing H, Bueno-de-Mesquita HB, Carneiro F, Pala V, Save VE, Vineis P, Tumino R, Panico S, Berglund G, Manjer J, Stenling R, Hallmans G, Martínez C, Dorronsoro M, Barricarte A, Navarro C, Quirós JR, Allen N, Key TJ, Binghan S, Caldas C, Linseisen J, Kaaks R, Overvad K, Tjønneland A, Büchner FC, Peeters PH, Numans ME, Clavel-Chapelon F, Trichopoulou A, Lund E, Jenab M, Rinaldi S, Ferrari P, Riboli E, González CA: Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST). Ann Oncol; 2008 Nov;19(11):1894-902
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST).
  • IL8 -251AA genotype was associated with a decreased risk of Hp(+) non-cardia GC (OR 0.51; 95% CI 0.32-0.81), mainly of the intestinal type.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628242.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United Kingdom / British Heart Foundation / / ; United Kingdom / Cancer Research UK / / ; United Kingdom / Department of Health / / ; United Kingdom / Medical Research Council / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukins; 0 / Lymphotoxin-alpha; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down






Advertisement